



- (51) International Patent Classification:
A61K 31/5377 (2006.01) C07D 413/14 (2006.01)
A61K 31/675 (2006.01) C12N 15/113 (2010.01)
- (21) International Application Number:
PCT/US2016/035671
- (22) International Filing Date:
3 June 2016 (03.06.2016)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
62/171,102 4 June 2015 (04.06.2015) US
- (71) Applicant: SAREPTA THERAPEUTICS, INC.
[US/US]; 4575 SW Research Way, Suite 200, Corvallis,
Oregon 97333 (US).
- (72) Inventors: MOURICH, Dan, V.; 5340 Vitae Springs Rd.
S., Salem, Oregon 97306 (US). HANSON, Gunnar, J.;
215 First Street, Cambridge, Massachusetts 02142 (US).
SCHNELL, Frederick, Joseph.; 1654 NW Crest Place,
Corvallis, Oregon 97330 (US). DWORZAK, Johannes,
Christian.; 55 Winchester Street, Unit 2, Medford, Mas-
sachusetts 02155 (US).

- (74) Agents: HARWOOD, Eric A. et al.; Seed Intellectual
Property Law Group PLLC, Suite 5400, 701 Fifth Avenue,
Seattle, Washington 98104-7064 (US).
- (81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: METHODS AND COMPOUNDS FOR TREATMENT OF LYMPHOCYTE-RELATED DISEASES AND CONDI-
TIONS





Figure 4

(57) Abstract: Methods for treatment of lymphocyte-related diseases and conditions, such as cancer and autoimmune diseases, are provided. The methods comprise administration of an effective amount of an oligomer to a patient in need thereof, wherein the oligomer comprises, inter alia, at least one intersubunit linkage having the following structure: wherein R¹, L¹, X, Y and Z are as defined herein.



Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

— with sequence listing part of description (Rule 5.2(a))

METHODS AND COMPOUNDS FOR TREATMENT OF LYMPHOCYTE-RELATED DISEASES AND CONDITIONS

5 STATEMENT REGARDING SEQUENCE LISTING

The Sequence Listing associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference into the specification. The name of the text file containing the Sequence Listing is 120178_50001WO_SEQUENCE_LISTING.txt. The text file is 8.2 KB, was created on 10 June 2, 2016, and is being submitted electronically via EFS-Web.

BACKGROUND

Technical Field

The present invention is generally related to oligonucleotide compounds (oligomers) and methods for their use as antisense compounds, and more particularly to 15 methods for use of the oligonucleotide compounds for treatment of lymphocyte-related diseases and conditions.

Description of the Related Art

Antisense oligonucleotides are useful tools for inhibiting gene expression and are the subject of ongoing investigation as therapeutic agents. 20 Lymphoid cells, including T lymphocytes and B lymphocytes, are important target cells for therapeutic antisense strategies. Lymphocytes are white blood cells that largely mediate the adaptive immune response. Lymphocytes include natural killer (NK) cells, T cells, and B cells. T cells and B cells are involved in cell-mediated immunity and humoral immunity, respectively, through their recognition of “non-self” antigens via 25 cell surface receptors. The antigen receptor of B cells is a membrane bound form of the immunoglobulin that they will secrete upon activation. Upon activation (*i.e.*, binding of the antigen to the B cell receptor), the B cell differentiates into plasma cells that secrete immunoglobulins. The antigen receptor of T cells is a membrane bound heterodimeric

receptor associated with the proteins of the CD3 complex. Most T lymphocytes have $\alpha:\beta$ heterodimeric receptors, but some T cells have $\gamma:\delta$ receptors.

Two simultaneous signals are required to activate a T lymphocyte. One signal is provided by a peptide bound to an MHC protein on the surface of an antigen presenting cell (APC). The peptide-MHC complex signals through the T cell receptor and its associated proteins. The second signal is provided by co-stimulatory molecules on the APC (*e.g.*, CD80 and CD86), which are recognized by a co-stimulatory receptor (*e.g.*, CD28) on the T cell surface. The combination of the two signals stimulates the T cell to proliferate and begin to differentiate into an effector T cell (*e.g.*, cytotoxic CD8⁺ T cell, T_H1 cell, T_H2 cell). Cytotoxic T cells kill infected target cells through the release of lytic granules into antigen-bearing target cells. T_H1 cells activate microbicidal properties of infected macrophages and induce B cells to produce opsonizing IgG antibodies. T_H2 cells activate naïve B cells to secrete IgM and induce production of other antibody isotypes. Regulatory T cells (Tregs) are a subpopulation of T cells involved in maintaining tolerance to self-antigens. Treg function or dysfunction may be an important factor in numerous pathological settings, including autoimmunity, allergy, infection, tumor immunity, organ transplantation, and fetal-maternal tolerance.

T cells are frequent therapeutic targets for inhibiting chronic inflammation or cytotoxicity associated with autoimmune diseases. For example, defective apoptosis of autoreactive T cells is implicated in the pathogenesis of multiple sclerosis. Antisense oligonucleotides for an X-linked inhibitor of apoptosis (XIAP) was found to increase susceptibility of T cells to activation-induced apoptosis *in vitro* and alleviated experimental autoimmune encephalomyelitis and prevented relapses in mice (Zehntner et al., 2007, J. Immunol. 179:7553-7560). In another example, migration of T lymphocytes into the intestinal mucosa plays a crucial role in the pathogenesis of inflammatory bowel disease (IBD) (*e.g.*, Crohn's disease or ulcerative colitis). Antisense inhibition of Smad7, an inhibitor of TGF- β 1 signaling that is overexpressed in inflammatory bowel disease mucosa and purified mucosal T cells, enabled IBD cell samples to respond to TGF- β 1 and downregulated proinflammatory cytokines (U.S. Patent Number 7,700,757; Monteleone et al., 2001, J. Clin. Invest. 108:601-609). In yet

another example, synovial T cells may play a crucial role in rheumatoid arthritis induction and promotion, in part due to the production of the proinflammatory cytokine IL-17. Antisense targeting of the transcription factor STAT4 in T lymphocytes suppressed clinical and histopathological signs of collagen-induced arthritis in mice
5 (Hildner et al., 2007, J. Immunol. 178:3427-3436).

The rejection of allogeneic transplants is largely mediated by T cells. Antisense oligonucleotides have been used to inhibit granzyme expression in cytotoxic T lymphocytes, which is associated with tissue destruction in transplantation models (Bailey et al., 2004, Eur. J. Immunol., 27:2302-2309).

10 HIV-infected T lymphocytes, particularly T helper lymphocytes, or CD4⁺ T lymphocytes, are targets for antisense strategies against HIV (Lisziewicz et al., 1994, Proc. Natl. Acad. Sci. USA 91:7942-7946; Zhang et al., 1995, Clin. Pharmacol. Ther. 58:44-53; Elmen et al., 2004, FEBS Lett. 578:285-90; Jakobsen et al., 2007, Retrovirology 4:29-41).

15 Lymphoid cells are also targeted by antisense oligonucleotides for antitumor therapy. By way of example, human T-cell leukemia virus type 1 (HTLV-1) infection is known to cause adult T cell leukemia. Inhibition of syncytium formation in T-cells was observed *in vitro* with antisense oligonucleotides targeting human T-cell leukemia virus type 1 HTLV-1 tax gene (Maeda et al., 1997, Leukemia 11:42-44). In
20 another example, antisense-mediated inhibition of the protooncogene c-myc inhibited DNA synthesis in T-leukemia cells of most patients (Venturelli et al., 1990 Cancer Res. 50:7371-7375). In yet another example, depletion of regulatory T cells with FOXP3-specific antisense oligonucleotides is being investigated as a way to enhance effector T cell response to tumors (Morse et al., 2012, Cancer Gene Ther. 19:30-37).

25 Functional efficacy of such antisense oligonucleotide based therapy is limited by insufficient cellular uptake of the oligonucleotide. Exogenous oligonucleotides are primarily taken up through fluid phase endocytosis at oligonucleotide concentrations greater than 1 μ M and endocytosis mediated by a receptor-like protein for lower concentrations (Beltinger et al., 1995, J. Clin. Invest.
30 95:1814-1823). Primary cells are known to incorporate oligonucleotides less efficiently than cell lines (Marti et al., 1992, Antisense Res. Dev. 2:27-39). Furthermore,


oligonucleotide uptake is heterogenous among different cell types. Among normal peripheral blood and bone marrow cells, myeloid cells and B cells preferably took up more oligonucleotides than T cells (Zhao et al., 1996, *Blood* 88:1788-1795). Other studies also showed preferential uptake of oligonucleotides by monocytes and B cells and very low uptake by T cells (Hartmann et al., 1998, *J. Pharmacol. Exp. Ther.* 285:920-928; Kronenwett et al., 1998, *Blood* 91:852-862). In fact, Hartmann et al. demonstrated that only 2% of T cells spontaneously incorporated FITC-labeled phosphorothioate oligonucleotides as measured by fluorescence intensity. Mitogen activation may increase oligonucleotide uptake (Kreig et al., 1991, *Antisense Res. Dev.* 1:161-171; Iversen et al., 1992, *Antisense Res. Dev.* 2:223-233). Cationic lipids have been used to enhance oligonucleotide uptake into T cells with variable results (Hartmann et al., supra; Kronenwett et al., supra).

T cells are important targets for inhibition by antisense oligonucleotides in the treatment of inflammatory, infectious, and neoplastic diseases. There is a need for alternative compositions and methods for improving uptake of antisense oligonucleotides into T cells. The present disclosure meets this need and further provides other related advantages.

BRIEF SUMMARY

Methods described herein are useful for treatment of various lymphocyte (e.g., T-cell) mediated diseases or conditions. While not wishing to be bound to any particular theory, the present applicants believe the presence of certain functional groups, such as guanidinyl, alkylguanidinyl and/or alkylaminyl groups, in antisense oligonucleotides unexpectedly enhances delivery of the antisense oligonucleotides to lymphocytes, such as T-cells. Accordingly, in one embodiment the present disclosure provides a method for treatment of a lymphocyte-related disease or condition, the method comprising administering an effective amount of an oligomer to a patient in need thereof, wherein the oligomer comprises a backbone having a sequence of morpholino ring structures joined by intersubunit linkages, the intersubunit linkages joining a 3'-end of one morpholino ring structure to a 5'-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing

moiety, such that the oligomer can bind in a sequence-specific manner to a target nucleic acid, wherein at least one of the intersubunit linkages has the following structure (I):



5

(I)

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R^1 , L^1 , X, Y and Z are as defined herein.

In certain embodiments, the method is for treatment of a T-cell related disease or condition, the method comprising contacting activated T-cells with the above described oligomer.

These and other aspects of the invention will be apparent upon reference to the following detailed description. To this end, various references are set forth herein which describe in more detail certain background information, procedures, compounds and/or compositions, and are each hereby incorporated by reference in their entirety.

15 BRIEF DESCRIPTION OF THE DRAWINGS

In the figures, identical reference numbers identify similar elements. The sizes and relative positions of elements in the figures are not necessarily drawn to scale and some of these elements are arbitrarily enlarged and positioned to improve figure legibility. Further, the particular shapes of the elements as drawn are not intended to convey any information regarding the actual shape of the particular elements, and have been solely selected for ease of recognition in the figures.

Figure 1 shows tissue distribution data for a guanidinyll modified oligomer relative to a peptide conjugated oligomer. AM - abdominal muscle; DP - diaphragm; HT - heart; KD - kidney; L2 - liver lobe 2; QC - quadriceps; CD8 - CD8 T-cells; Act T reg - activated T-regulatory cells; Rest Treg- resting T regulatory cells.

25

Figure 2 is a graph showing activity of representative oligomers in activated T cells.

Figure 3 presents activity data in B cells.

Figure 4 compares activity of a guanidinylyl modified oligomer in
5 activated T cells relative to peptide conjugated oligomers.

Figure 5 illustrates comparative activity of a guanidinylyl modified oligomer in resting T cells relative to peptide conjugated oligomers.

Figure 6 presents activity of a guanidinylyl modified oligomer in B cells relative to peptide conjugated oligomers.

10 Figure 7 is a graphical presentation of in vivo data for oligomer activities in activated T cells.

Figure 8 shows in vivo activity data in resting T cells.

Figure 9 presents in vivo activity of various oligomers in T cells.

Figure 10 provides in vivo activity of various oligomers in macrophages.

15 DETAILED DESCRIPTION

In the following description, certain specific details are set forth in order to provide a thorough understanding of various embodiments. However, one skilled in the art will understand that the invention may be practiced without these details. In other instances, well-known structures have not been shown or described in detail to
20 avoid unnecessarily obscuring descriptions of the embodiments. Unless the context requires otherwise, throughout the specification and claims which follow, the word “comprise” and variations thereof, such as, “comprises” and “comprising” are to be construed in an open, inclusive sense, that is, as “including, but not limited to.” Further, headings provided herein are for convenience only and do not interpret the
25 scope or meaning of the claimed invention.

Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” in various
30 places throughout this specification are not necessarily all referring to the same

embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments. Also, as used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise. It should also be noted
5 that the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.

The terms below, as used herein, have the following meanings, unless indicated otherwise:

- “Amino” refers to the -NH_2 radical.
- 10 “Cyano” or “nitrile” refers to the -CN radical.
- “Hydroxy” or “hydroxyl” refers to the -OH radical.
- “Imino” refers to the =NH substituent.
- “Guanidinyll” refers to the -NHC(=NH)NH_2 substituent.
- “Nitro” refers to the -NO_2 radical.
- 15 “Oxo” refers to the =O substituent.
- “Thioxo” refers to the =S substituent.
- “Alkyl” refers to a straight or branched hydrocarbon chain radical which is saturated or unsaturated (*i.e.*, contains one or more double and/or triple bonds), having from one to thirty carbon atoms, and which is attached to the rest of the
20 molecule by a single bond. Alkyls comprising any number of carbon atoms from 1 to 30 are included. An alkyl comprising up to 30 carbon atoms is referred to as a $\text{C}_1\text{-C}_{30}$ alkyl, likewise, for example, an alkyl comprising up to 12 carbon atoms is a $\text{C}_1\text{-C}_{12}$ alkyl. Alkyls (and other moieties defined herein) comprising other numbers of carbon atoms are represented similarly. Alkyl groups include, but are not limited to, $\text{C}_1\text{-C}_{30}$
25 alkyl, $\text{C}_1\text{-C}_{20}$ alkyl, $\text{C}_1\text{-C}_{15}$ alkyl, $\text{C}_1\text{-C}_{10}$ alkyl, $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_4$ alkyl, $\text{C}_1\text{-C}_3$ alkyl, $\text{C}_1\text{-C}_2$ alkyl, $\text{C}_2\text{-C}_8$ alkyl, $\text{C}_3\text{-C}_8$ alkyl and $\text{C}_4\text{-C}_8$ alkyl. Representative alkyl groups include, but are not limited to, methyl, ethyl, *n*-propyl, 1-methylethyl (*iso*-propyl), *n*-butyl, *i*-butyl, *s*-butyl, *n*-pentyl, 1,1-dimethylethyl (*t*-butyl), 3-methylhexyl, 2-methylhexyl, ethenyl, prop-1-enyl, but-1-enyl, pent-1-enyl,
30 penta-1,4-dienyl, ethynyl, propynyl, but-2-ynyl, but-3-ynyl, pentynyl, hexynyl, and the

like. Unless stated otherwise specifically in the specification, an alkyl group is optionally substituted as described below.

“Alkylguanidiny” refers to a radical of the formula $-NR_a C(=NR_a)N(R_a)_2$ where each R_a is, independently, H or an alkyl radical as defined above, provided at least one R_a is an alkyl radical. Unless stated otherwise specifically in the specification, an alkylguanidiny group is optionally substituted as described below.

“Alkylene” or “alkylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group. Alkylenes may be saturated or unsaturated (*i.e.*, contains one or more double and/or triple bonds). Representative alkylenes include, but are not limited to, C_1 - C_{12} alkylene, C_1 - C_8 alkylene, C_1 - C_6 alkylene, C_1 - C_4 alkylene, C_1 - C_3 alkylene, C_1 - C_2 alkylene, C_1 alkylene. Representative alkylene groups include, but are not limited to, methylene, ethylene, propylene, *n*-butylene, ethenylene, propenylene, *n*-butenylene, propynylene, *n*-butynylene, and the like. The alkylene chain is attached to the rest of the molecule through a single or double bond and to the radical group through a single or double bond. The points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkylene chain is optionally substituted as described below. For example, in certain embodiments the alkylene is substituted with oxo.

“Aminoalkylene” refers to an alkylene as defined above, wherein the hydrocarbon chain is interrupted by (*i.e.*, includes) at least one nitrogen atom. The nitrogen atom(s) may be at any position in the hydrocarbon chain, including the terminal ends (*i.e.*, the nitrogen atom may link the hydrocarbon chain to the rest of the molecule and/or to the radical group). Unless stated otherwise specifically in the specification, an aminoalkylene group is optionally substituted as described below.

“Oxyalkylene” refers to an alkylene as defined above, wherein the hydrocarbon chain is interrupted by (*i.e.*, includes) at least one oxygen atom. The oxygen atom(s) may be at any position in the hydrocarbon chain, including the terminal ends (*i.e.*, the oxygen atom may link the hydrocarbon chain to the rest of the molecule

and/or to the radical group). Unless stated otherwise specifically in the specification, an oxyalkylene group is optionally substituted as described below.

“Thioalkylene” refers to an alkylene as defined above, wherein the hydrocarbon chain is interrupted by (*i.e.*, includes) at least one sulfur atom. The sulfur atom(s) may be at any position in the hydrocarbon chain, including the terminal ends (*i.e.*, the sulfur atom may link the hydrocarbon chain to the rest of the molecule and/or to the radical group). Unless stated otherwise specifically in the specification, a thioalkylene group is optionally substituted as described below.

“Alkylaminyl” refers to a radical of the formula $-NHR_a$ or $-NR_aR_a$ where each R_a is, independently, an alkyl radical as defined above. Unless stated otherwise specifically in the specification, an alkylamino group is optionally substituted as described below.

“Fused” refers to any ring structure described herein which is fused to an existing ring structure. When the fused ring is a heterocyclyl ring or a heteroaryl ring, any carbon atom on the existing ring structure which becomes part of the fused heterocyclyl ring or the fused heteroaryl ring may be replaced with a nitrogen atom.

“Halo” or “halogen” refers to bromo, chloro, fluoro or iodo.

“Heterocyclyl”, “heterocycle” or “heterocyclic ring” refers to a stable 3- to 24-membered non-aromatic ring radical comprising 2 to 23 carbon atoms and from one to 8 heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorous and sulfur. Unless stated otherwise specifically in the specification, the heterocyclyl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized; and the heterocyclyl radical may be partially or fully saturated. Examples of such heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolanyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholanyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholanyl, thiamorpholanyl,

1-oxo-thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, 12-crown-4, 15-crown-5, 18-crown-6, 21-crown-7, aza-18-crown-6, diaza-18-crown-6, aza-21-crown-7, and diaza-21-crown-7. Unless stated otherwise specifically in the specification, a heterocyclyl group may be optionally substituted.

5 All the above groups may be either substituted or unsubstituted. The term “substituted” as used herein means any of the above groups (*e.g.*, alkyl, alkylguanidinyl, alkylene, aminoalkylene, oxyalkylene, thioalkylene, alkylaminyl and/or heterocyclyl), may be further functionalized wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atom substituent. Unless stated specifically in

10 the specification, a substituted group may include one or more substituents selected from: amino, oxo, -CO₂H, nitrile, nitro, -CONH₂, hydroxyl, imino, thio, alkyl, alkylene, alkoxy, alkoxyalkyl, alkylcarbonyl, alkyloxycarbonyl, aryl, aralkyl, arylcarbonyl, aryloxycarbonyl, aralkylcarbonyl, aralkyloxycarbonyl, aryloxy, cycloalkyl, cycloalkylalkyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl, cycloalkyloxycarbonyl,

15 heterocyclyl, heteroaryl, dialkylamines, arylamines, alkylarylamines, diarylamines, N-oxides, imides, and enamines; a silicon atom in groups such as trialkylsilyl groups, dialkylarylsilyl groups, alkylarylsilyl groups, triarylsilyl groups, perfluoroalkyl or perfluoroalkoxy, for example, trifluoromethyl or trifluoromethoxy. “Substituted” also means any of the above groups in which one or more hydrogen atoms are replaced by a

20 higher-order bond (*e.g.*, a double- or triple-bond) to a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles. For example, “substituted” includes any of the above groups in which one or more hydrogen atoms are replaced with -NR_gC(=O)NR_gR_h, -NR_gC(=O)OR_h, -NR_gSO₂R_h, -OC(=O)NR_gR_h, -OR_g, -SR_g, -SOR_g, -SO₂R_g, -OSO₂R_g,

25 -SO₂OR_g, =NSO₂R_g, and -SO₂NR_gR_h. “Substituted” also means any of the above groups in which one or more hydrogen atoms are replaced with -C(=O)R_g, -C(=O)OR_g, -CH₂SO₂R_g, -CH₂SO₂NR_gR_h, -SH, -SR_g or -SSR_g. In the foregoing, R_g and R_h are the same or different and independently hydrogen, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, *N*-heterocyclyl,

30 heterocyclylalkyl, heteroaryl, *N*-heteroaryl and/or heteroarylalkyl. In addition, each of the foregoing substituents may also be optionally substituted with one or more of the

above substituents. Furthermore, any of the above groups may be substituted to include one or more internal oxygen or sulfur atoms. For example, an alkyl group may be substituted with one or more internal oxygen atoms to form an ether or polyether group. Similarly, an alkyl group may be substituted with one or more internal sulfur atoms to
5 form a thioether, disulfide, etc.

The terms "antisense oligomer" or "antisense compound" are used interchangeably and refer to a sequence of subunits, each having a base carried on a backbone subunit composed of ribose or other pentose sugar or morpholino group, and where the backbone groups are linked by intersubunit linkages that allow the bases in
10 the compound to hybridize to a target sequence in a nucleic acid (typically an RNA) by Watson-Crick base pairing, to form a nucleic acid:oligomer heteroduplex within the target sequence. The oligomer may have exact sequence complementarity to the target sequence or near complementarity. Such antisense oligomers are designed to block or inhibit translation of the mRNA containing the target sequence, and may be said to be
15 "directed to" a sequence with which it hybridizes.

A "morpholino oligomer" or "PMO" refers to a polymeric molecule having a backbone which supports bases capable of hydrogen bonding to typical polynucleotides, wherein the polymer lacks a pentose sugar backbone moiety, and more specifically a ribose backbone linked by phosphodiester bonds which is typical of
20 nucleotides and nucleosides, but instead contains a ring nitrogen with coupling through the ring nitrogen. An exemplary "morpholino" oligomer comprises morpholino subunit structures linked together by (thio)phosphoramidate or (thio)phosphorodiamidate linkages, joining the morpholino nitrogen of one subunit to the 5' exocyclic carbon of an adjacent subunit, each subunit comprising a purine or pyrimidine base-pairing moiety
25 effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide. Morpholino oligomers (including antisense oligomers) are detailed, for example, in U.S. Pat. Nos. 5,698,685; 5,217,866; 5,142,047; 5,034,506; 5,166,315; 5,185,444; 5,521,063; 5,506,337 and pending US patent applications 12/271,036; 12/271,040; and PCT publication number WO/2009/064471 all of which are incorporated herein by reference
30 in their entirety. Representative PMOs include PMOs wherein the intersubunit linkages are linkage (A1).

A "phosphoramidate" group comprises phosphorus having three attached oxygen atoms and one attached nitrogen atom, while a "phosphorodiamidate" group comprises phosphorus having two attached oxygen atoms and two attached nitrogen atoms. In the uncharged or the modified intersubunit linkages of the oligomers
5 described herein and co-pending US Patent Application Nos. 61/349,783 and 11/801,885, one nitrogen is always pendant to the backbone chain. The second nitrogen, in a phosphorodiamidate linkage, is typically the ring nitrogen in a morpholino ring structure.

"Thiophosphoramidate" or "thiophosphorodiamidate" linkages are
10 phosphoramidate or phosphorodiamidate linkages, respectively, wherein one oxygen atom, typically the oxygen pendant to the backbone, is replaced with sulfur.

"Intersubunit linkage" refers to the linkage connecting two morpholino subunits, for example structure (I).

"Charged", "uncharged", "cationic" and "anionic" as used herein refer to
15 the predominant state of a chemical moiety at near-neutral pH, e.g., about 6 to 8. For example, the term may refer to the predominant state of the chemical moiety at physiological pH, that is, about 7.4.

"Lower alkyl" refers to an alkyl radical of one to six carbon atoms, as exemplified by methyl, ethyl, n-butyl, i-butyl, t-butyl, isoamyl, n-pentyl, and isopentyl. In
20 certain embodiments, a "lower alkyl" group has one to four carbon atoms. In other embodiments a "lower alkyl" group has one to two carbon atoms; i.e. methyl or ethyl. Analogously, "lower alkenyl" refers to an alkenyl radical of two to six, preferably three or four, carbon atoms, as exemplified by allyl and butenyl.

A "non-interfering" substituent is one that does not adversely affect the
25 ability of an antisense oligomer as described herein to bind to its intended target. Such substituents include small and/or relatively non-polar groups such as methyl, ethyl, methoxy, ethoxy, or fluoro.

An oligonucleotide or antisense oligomer "specifically hybridizes" to a target polynucleotide if the oligomer hybridizes to the target under physiological
30 conditions, with a T_m greater than 37 °C, greater than 45 °C, preferably at least 50 °C, and typically 60 °C-80 °C or higher. The " T_m " of an oligomer is the temperature at

which 50% hybridizes to a complementary polynucleotide. T_m is determined under standard conditions in physiological saline, as described, for example, in Miyada *et al.*, *Methods Enzymol.* **154**:94-107 (1987). Such hybridization may occur with "near" or "substantial" complementary of the antisense oligomer to the target sequence, as well as
5 with exact complementarity.

Polynucleotides are described as "complementary" to one another when hybridization occurs in an antiparallel configuration between two single-stranded polynucleotides. Complementarity (the degree that one polynucleotide is complementary with another) is quantifiable in terms of the proportion of bases in
10 opposing strands that are expected to form hydrogen bonds with each other, according to generally accepted base-pairing rules.

A first sequence is an "antisense sequence" with respect to a second sequence if a polynucleotide whose sequence is the first sequence specifically binds to, or specifically hybridizes with, the second polynucleotide sequence under physiological
15 conditions.

The term "targeting sequence" is the sequence in the oligonucleotide analog that is complementary (meaning, in addition, substantially complementary) to the target sequence in the RNA genome. The entire sequence, or only a portion, of the analog compound may be complementary to the target sequence. For example, in some
20 embodiments an analog having 20 bases, only 12-14 may be targeting sequences. Typically, the targeting sequence is formed of contiguous bases in the analog, but may alternatively be formed of non-contiguous sequences that when placed together, *e.g.*, from opposite ends of the analog, constitute sequence that spans the target sequence.

Target and targeting sequences are described as "complementary" to one
25 another when hybridization occurs in an antiparallel configuration. A targeting sequence may have "near" or "substantial" complementarity to the target sequence and still function for the purpose of the presently described methods, that is, still be "complementary." Preferably, the oligonucleotide analog compounds employed in the presently described methods have at most one mismatch with the target sequence out of
30 10 nucleotides, and preferably at most one mismatch out of 20. Alternatively, the antisense oligomers employed have at least 90% sequence homology, and preferably at

least 95% sequence homology, with the exemplary targeting sequences as designated herein. For purposes of complementary binding to an RNA target, and as discussed below, a guanine base may be complementary to either a cytosine or uracil RNA base.

A "heteroduplex" refers to a duplex between an oligonucleotide analog and the complementary portion of a target RNA. A "nuclease-resistant heteroduplex" refers to a heteroduplex formed by the binding of an antisense oligomer to its complementary target, such that the heteroduplex is substantially resistant to *in vivo* degradation by intracellular and extracellular nucleases, such as RNase H, which are capable of cutting double-stranded RNA/RNA or RNA/DNA complexes.

10 An agent is "actively taken up by mammalian cells" when the agent can enter the cell by a mechanism other than passive diffusion across the cell membrane. The agent may be transported, for example, by "active transport", referring to transport of agents across a mammalian cell membrane by *e.g.* an ATP-dependent transport mechanism, or by "facilitated transport", referring to transport of antisense agents
15 across the cell membrane by a transport mechanism that requires binding of the agent to a transport protein, which then facilitates passage of the bound agent across the membrane.

The terms "modulating expression" and/or "antisense activity" refer to the ability of an antisense oligomer to either enhance or, more typically, reduce the
20 expression of a given protein, by interfering with the expression or translation of RNA. In the case of reduced protein expression, the antisense oligomer may directly block expression of a given gene, or contribute to the accelerated breakdown of the RNA transcribed from that gene. Morpholino oligomers as described herein are believed to act via the former (steric blocking) mechanism. Preferred antisense targets for steric
25 blocking oligomers include the ATG start codon region, splice sites, regions closely adjacent to splice sites, and 5'-untranslated region of mRNA, although other regions have been successfully targeted using morpholino oligomers.

An "effective amount" or "therapeutically effective amount" refers to an amount of antisense oligomer administered to a mammalian subject, either as a single
30 dose or as part of a series of doses, which is effective to produce a desired therapeutic effect, typically by inhibiting translation of a selected target nucleic acid sequence.

"Treatment" of an individual (e.g. a mammal, such as a human) or a cell is any type of intervention used in an attempt to alter the natural course of the individual or cell. Treatment includes, but is not limited to, administration of a pharmaceutical composition, and may be performed either prophylactically or subsequent to the
5 initiation of a pathologic event or contact with an etiologic agent.

As used herein, "T cells," also known as "T lymphocytes," means a subset of lymphocytes defined by their development in the thymus and by heterodimeric receptors (T cell receptors) associated with the proteins of the CD3 complex. Most T lymphocytes have $\alpha:\beta$ heterodimeric receptors, but some T cells have
10 $\gamma:\delta$ receptors. T cells include several subsets, each with distinct functions: T helper cells (T_H cells or $CD4^+$ T cells), cytotoxic T cells ($CD8^+$ T cells, T_C cells, or CTLs), memory T cells, regulatory T cells (T_{reg} cells), and natural killer T cells (NKT cells).

As used herein, an "activated T cells" is a T cell that has been signaled to proliferate and differentiate into an effector cell. Two simultaneous signals are required
15 to activate a T cell. One signal is provided by a peptide bound to an MHC protein on the surface of an antigen presenting cell (APC). The peptide-MHC complex signals through the T cell receptor and its associated proteins. The second signal is provided by co-stimulatory molecules on the APC (e.g., CD80 and CD86), which are recognized by a co-stimulatory receptor (e.g., CD28) on the T cell surface. The combination of the
20 two signals stimulates the T cell to proliferate and begin to differentiate into an effector cell.

As used herein, "B cells," also known as "B lymphocytes" means a subset of lymphocytes having an immunoglobulin molecule as a cell surface receptor (B cell receptor). Upon activation by an antigen (*i.e.*, binding of the antigen to the B cell
25 receptor), a B cell differentiates into plasma cells producing antibody of the same specificity as its initial receptor.

A. Methods


As noted above, one embodiment of the present disclosure is directed to methods for treatment of lymphocyte-related diseases or conditions, for example T-cell
30 mediated diseases. In general, the methods comprise administering an oligomer

comprising a guanidinyl, alkylguanidinyl and/or alkylaminyl moiety to a patient in need thereof. For example, in some embodiments the oligomer is a morpholino oligomer.

The guanidinyl, alkylguanidinyl and/or alkylaminyl moiety may be present at any location within the oligomer, and in certain embodiments the guanidinyl,

5 alkylguanidinyl and/or alkylaminyl moiety is bound to the intersubunit linkage of a morpholino oligomer.

In other embodiments, a method for treatment of a lymphocyte-related disease or condition is provided, the method comprising administering an effective amount of an oligomer to a patient in need thereof, wherein the oligomer comprises a backbone having a sequence of morpholino ring structures joined by intersubunit linkages, the intersubunit linkages joining a 3'-end of one morpholino ring structure to a 5'-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing moiety, such that the oligomer can bind in a sequence-specific manner to a target nucleic acid, wherein at least one of the intersubunit linkages has the following structure (I):



(I)

or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein:

20 R^1 is guanidinyl, alkylguanidinyl or alkylaminyl;

L^1 is absent or present, and when present is selected from alkylene, aminoalkylene, oxyalkylene and thioalkylene;


X is, at each occurrence, independently S or O;

Y is, at each occurrence, independently $-O-$ or $-NH-$; and

25 Z is an optionally substituted 5, 6 or 7-membered heterocyclic ring.

In certain embodiments of the above, the lymphocyte-related disease or condition is a T-cell related disease or condition.

Various different oligomers are useful for the described methods. For example, morpholino oligomers are employed in various embodiments. In some of these embodiments, the morpholino ring structures have the following structure (i):




5

(i)


wherein B is, at each occurrence, independently a base-pairing moiety, such as A, C, G, T, I, U and the like.

In various embodiments of the above, Z is an optionally substituted 5 or 6-membered heterocyclic ring. For example, in some embodiments Z is pyrrolidinyl, or piperidinyl. In more specific embodiments, Z is piperidinyl.

In even other embodiments, Z has one of the following structures:




For example, in further embodiments Z has the following structure:



15

The position of the R¹-L¹ moiety on the Z ring is not particularly limited and various substitution patterns are expected to result in oligomers having the desired properties (*i.e.*, effective delivery to lymphocytes and treatment of lymphocyte-related diseases and/or conditions). In certain embodiments, Z has the following structure:




20

In any one of the foregoing embodiments, R¹ is guanidinyl.

In other of any one of the foregoing embodiments, R¹ is alkylguanidinyl.

For example, in some embodiments the alkylguanidinyl has the following structure:




wherein R' is C_1 - C_6 alkyl. In further of these embodiments, R' is methyl.

In still more of any one of the foregoing embodiments, R^1 is alkylaminyl. For example, in certain of these embodiments the alkylaminyl is $-NHR''$,
 5 where R'' is C_1 - C_6 alkyl. In further of these embodiments, R'' is methyl.

In some embodiments, L^1 is absent and R^1 is bound directly to the Z ring. In other embodiments, L^1 is selected from an appropriate length alkylene, aminoalkylene, oxyalkylene and thioalkylene such that delivery and or activity of the oligomer is optimized.

10 In various embodiments, X is O. In other embodiments, Y is $-O-$. In still other embodiments, X is O and Y is $-O-$.

In addition to one or more intersubunit linkages of structure (I), the oligomers typically contain additional intersubunit linkages of various structures. The structures of the other intersubunit linkages are not particularly limited, provided the
 15 oligomer comprises at least one intersubunit linkage of structure (I). In this regard, any of the intersubunit linkages known to one of ordinary skill in the art can be employed, and such intersubunit linkages will be selected to optimize the desired properties of oligomer. In some embodiments, at least one of the intersubunit linkages has the following structure (II):



20

(II)

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:

R^2 and R^3 are each independently H or C_1 - C_6 alkyl,

X' is S or O; and


25

Y' is $-O-$ or $-NH-$.


In certain of the above embodiments, R^2 and R^3 are each methyl. In other embodiments, X' is O. In more embodiments, Y' is $-O-$.

In some of the foregoing embodiments, each intersubunit linkage in the oligomer is either linkage (I) or linkage (II). That is, certain embodiments are directed to oligomers having intersubunit linkages selected from structures (I) and (II), provided
5 at least one intersubunit linkage has structure (I).


In some more embodiments of the above, at least one of the intersubunit linkages has the following structure:



In some other embodiments of the above, at least one of the intersubunit linkages has the following structure:




In even other embodiments of the above, at least one of the intersubunit linkages has the following structure:



In certain embodiments, the lymphocyte-related disease or condition is a T-cell-related disease or condition. In some of these embodiments, the T-cell is an activated T-cell. In other embodiments, the T-cell is a CD4 or CD8 cell.
15

Various lymphocyte-related diseases or conditions can be treated by the disclosed methods. In various embodiments, the disease or condition is cancer or an autoimmune disease or condition.

In still other embodiments, a method for treatment of a T-cell related disease or condition is provided, the method comprising contacting activated T-cells with an oligomer comprising a backbone having a sequence of morpholino ring structures joined by intersubunit linkages, the intersubunit linkages joining a 3'-end of one morpholino ring structure to a 5'-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing moiety, such that the oligomer can bind in a sequence-specific manner to a target nucleic acid, wherein at least one of the intersubunit linkages has the following structure (I):



(I)


or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:

- 15 R^1 is guanidiny, alkylguanidiny or alkylaminyl;
- L^1 is absent or present, and when present is selected from alkylene, aminoalkylene, oxyalkylene, oxoalkylene and thioalkylene;
- X is, at each occurrence, independently S or O;
- Y is, at each occurrence, independently $-O-$ or $-NH-$; and
- 20 Z is an optionally substituted 5, 6 or 7-membered heterocyclic ring.

In various other embodiments of the foregoing, the oligomer and intersubunit linkages are as defined above.

Still other embodiments are directed to use of an oligomer comprising a backbone having a sequence of morpholino ring structures joined by intersubunit linkages, the intersubunit linkages joining a 3'-end of one morpholino ring structure to a 5'-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing moiety, such that the oligomer can bind in a sequence-

specific manner to a target nucleic acid, wherein at least one of the intersubunit linkages has the following structure (I):



5 or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:

R^1 is guanidinyl, alkylguanidinyl or alkylaminyl;

L^1 is absent or present, and when present is selected from alkylene, aminoalkylene, oxyalkylene, oxoalkylene and thioalkylene;

X is, at each occurrence, independently S or O;

10 Y is, at each occurrence, independently $-O-$ or $-NH-$; and

Z is an optionally substituted 5, 6 or 7-membered heterocyclic ring, for preparation of a pharmaceutical composition for treatment of a lymphocyte-related disease or condition.


In various other embodiments of the foregoing, the oligomer and
15 intersubunit linkages are as defined above.

Another embodiment provides a method for improving delivery of an oligonucleotide to lymphocytes, such as T cell. The method comprises modifying the oligonucleotide to contain an intersubunit linkage having structure (I).

B. Properties of the Oligomers

20 As noted above, the present disclosure is directed to methods for treatment of lymphocyte-related diseases or conditions by administration of oligomers comprising various intersubunit linkage modifications, such as linkages comprising guanidinyl, alkylguanidinyl and/or alkylaminyl moieties. In certain embodiments, the oligomer comprises a backbone comprising a sequence of morpholino ring structures
25 joined by intersubunit linkages, the intersubunit linkages joining a 3'-end of one morpholino ring structure to a 5'-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing moiety, such that the

oligomer can bind in a sequence-specific manner to a target nucleic acid. The morpholino ring structures may have the following structure (i):



(i)

5 wherein B is, at each occurrence, independently a base-pairing moiety.

Each morpholino ring structure supports a base pairing moiety (B), to form a sequence of base pairing moieties which is typically designed to hybridize to a selected antisense target in a cell or in a subject being treated. The base pairing moiety may be a purine or pyrimidine found in native DNA or RNA (A, G, C, T, or U) or an analog, such as hypoxanthine (the base component of the nucleoside inosine) or 5-
 10 methyl cytosine. Analog bases that confer improved binding affinity to the oligomer can also be utilized. Exemplary analogs in this regard include C5-propynyl-modified pyrimidines, 9-(aminoethoxy)phenoxazine (G-clamp) and the like.

The oligomer may be modified, in accordance with an aspect of the
 15 invention, to include one or more linkages comprising guanidinyll, alkylguanidinyll and/or alkylaminyll moieties, e.g. up to about 1 per every 2-5 linkages, typically 3-5 per every 10 linkages. Certain embodiments also include one or more linkages comprising guanidinyll, alkylguanidinyll and/or alkylaminyll moieties.

Oligomers for use in antisense applications generally range in length
 20 from about 10 to about 40 subunits, more preferably about 15 to 25 subunits. For example, in some embodiments, an oligomer of the invention having 19-20 subunits, a useful length for an antisense oligomer, may ideally have one to seven, e.g. four to six, or three to five linkages comprising guanidinyll, alkylguanidinyll and/or alkylaminyll moieties.

25 The morpholino subunits may also be linked by non-phosphorus-based intersubunit linkages.

Other oligonucleotide analog linkages which are uncharged in their unmodified state but which could also bear a pendant amine substituent can also be used. For example, in certain embodiments a 5' nitrogen atom on a morpholino ring could be employed in a sulfamide linkage (or a urea linkage, where phosphorus is replaced with carbon or sulfur, respectively).

In some embodiments for antisense applications, the oligomer may be 100% complementary to the nucleic acid target sequence, or it may include mismatches, *e.g.*, to accommodate variants, as long as a heteroduplex formed between the oligomer and nucleic acid target sequence is sufficiently stable to withstand the action of cellular nucleases and other modes of degradation which may occur *in vivo*. Mismatches, if present, are less destabilizing toward the end regions of the hybrid duplex than in the middle. The number of mismatches allowed will depend on the length of the oligomer, the percentage of G:C base pairs in the duplex, and the position of the mismatch(es) in the duplex, according to well understood principles of duplex stability. Although such an antisense oligomer is not necessarily 100% complementary to the nucleic acid target sequence, it is effective to stably and specifically bind to the target sequence, such that a biological activity of the nucleic acid target, *e.g.*, expression of encoded protein(s), is modulated.

The stability of the duplex formed between an oligomer and the target sequence is a function of the binding T_m and the susceptibility of the duplex to cellular enzymatic cleavage. The T_m of an antisense compound with respect to complementary-sequence RNA may be measured by conventional methods, such as those described by Hames *et al.*, *Nucleic Acid Hybridization*, IRL Press, 1985, pp.107-108 or as described in Miyada C.G. and Wallace R.B., 1987, *Oligonucleotide hybridization techniques*, *Methods Enzymol.* Vol. 154 pp. 94-107.

In some embodiments, each antisense oligomer has a binding T_m , with respect to a complementary-sequence RNA, of greater than human body temperature or in other embodiments greater than 50°C. In other embodiments T_m 's are in the range 60-80°C or greater. According to well known principles, the T_m of an oligomer compound, with respect to a complementary-based RNA hybrid, can be increased by increasing the ratio of C:G paired bases in the duplex, and/or by increasing the length

(in base pairs) of the heteroduplex. At the same time, for purposes of optimizing cellular uptake, it may be advantageous to limit the size of the oligomer. For this reason, compounds that show high T_m (50°C or greater) at a length of 20 bases or less are generally preferred over those requiring greater than 20 bases for high T_m values.

5 For some applications, longer oligomers, for example longer than 20 bases may have certain advantages. For example, in certain embodiments longer oligomers may find particular utility for use in exon skipping or splice modulation.

The targeting sequence bases may be normal DNA bases or analogues thereof, *e.g.*, uracil and inosine that are capable of Watson-Crick base pairing to target-
10 sequence RNA bases.

The oligomers may also incorporate guanine bases in place of adenine when the target nucleotide is a uracil residue. This is useful when the target sequence varies across different target alleles or viral species and the variation at any given nucleotide residue is either cytosine or uracil. By utilizing guanine in the targeting
15 oligomer at the position of variability, the well-known ability of guanine to base pair with uracil (termed C/U:G base pairing) can be exploited. By incorporating guanine at these locations, a single oligomer can effectively target a wider range of RNA target variability.

The compounds (*e.g.*, oligomers, morpholino subunits, intersubunit
20 linkages, etc.) may exist in different isomeric forms, for example structural isomers (*e.g.*, tautomers). With regard to stereoisomers, the compounds may have chiral centers and may occur as racemates, enantiomerically enriched mixtures, individual enantiomers, mixture or diastereomers or individual diastereomers. All such isomeric forms are included within the present invention, including mixtures thereof. The
25 compounds may also possess axial chirality which may result in atropisomers. Furthermore, some of the crystalline forms of the compounds may exist as polymorphs, which are included in the present invention. In addition, some of the compounds may also form solvates with water or other organic solvents. Such solvates are similarly included within the scope of this invention.

30 The oligomers described herein may be used in methods of inhibiting production of a protein or replication of a virus. Accordingly, in one embodiment a

nucleic acid encoding such a protein is exposed to an oligomer as disclosed herein. In further embodiments of the foregoing, the antisense oligomer comprises one or more intersubunit linkages comprising a guanidinyl, alkylguanidinyl and/or alkylaminyl moiety, as disclosed herein, and the base pairing moieties B form a sequence effective to hybridize to a portion of the nucleic acid at a location effective to inhibit production of the protein. In one embodiment, the location is an ATG start codon region of an mRNA, a splice site of a pre-mRNA, or a viral target sequence as described below.

In one embodiment, the oligomer has a T_m with respect to binding to the target sequence of greater than about 50 °C, and it is taken up by mammalian cells or bacterial cells.

The preparation and properties of morpholino oligomers is described in more detail below and in U.S. Patent No. 5,185,444 and WO/2009/064471, each of which is hereby incorporated by reference in their entirety.

C. Formulation and Administration of the Oligomers

The present disclosure also provides for formulation and delivery of the disclosed oligomers (e.g., for treatment of lymphocyte-related diseases and/or conditions). Accordingly, in one embodiment the present disclosure is directed to a composition comprising an oligomer as disclosed herein and a pharmaceutically acceptable vehicle. Other embodiments are directed to use of such a composition for treatment of a lymphocyte-related disease and/or condition.

Effective delivery of the antisense oligomer to the target nucleic acid is an important aspect of treatment. Routes of antisense oligomer delivery include, but are not limited to, various systemic routes, including oral and parenteral routes, e.g., intravenous, subcutaneous, intraperitoneal, and intramuscular, as well as inhalation, transdermal and topical delivery. The appropriate route may be determined by one of skill in the art, as appropriate to the condition of the subject under treatment. For example, the oligomer may be delivered directly to the bloodstream.

The antisense oligomer may be administered in any convenient vehicle which is physiologically and/or pharmaceutically acceptable. Such a composition may include any of a variety of standard pharmaceutically acceptable carriers employed by

those of ordinary skill in the art. Examples include, but are not limited to, saline, phosphate buffered saline (PBS), water, aqueous ethanol, emulsions, such as oil/water emulsions or triglyceride emulsions, tablets and capsules. The choice of suitable physiologically acceptable carrier will vary depending upon the chosen mode of
5 administration.

The compounds (e.g., oligomers) of the present invention may generally be utilized as the free acid or free base. Alternatively, the compounds of this invention may be used in the form of acid or base addition salts. Acid addition salts of the free amino compounds of the present invention may be prepared by methods well known in
10 the art, and may be formed from organic and inorganic acids. Suitable organic acids include maleic, fumaric, benzoic, ascorbic, succinic, methanesulfonic, acetic, trifluoroacetic, oxalic, propionic, tartaric, salicylic, citric, gluconic, lactic, mandelic, cinnamic, aspartic, stearic, palmitic, glycolic, glutamic, and benzenesulfonic acids. Suitable inorganic acids include hydrochloric, hydrobromic, sulfuric, phosphoric, and
15 nitric acids. Base addition salts included those salts that form with the carboxylate anion and include salts formed with organic and inorganic cations such as those chosen from the alkali and alkaline earth metals (for example, lithium, sodium, potassium, magnesium, barium and calcium), as well as the ammonium ion and substituted derivatives thereof (for example, dibenzylammonium, benzylammonium, 2-
20 hydroxyethylammonium, and the like). Thus, the term “pharmaceutically acceptable salt” of structure (I) is intended to encompass any and all acceptable salt forms.

In addition, prodrugs are also included within the context of this invention. Prodrugs are any covalently bonded carriers that release a compound of structure (I) in vivo when such prodrug is administered to a patient. Prodrugs are
25 generally prepared by modifying functional groups of the active moiety in a way such that the modification is cleaved, either by routine manipulation or in vivo, yielding the parent compound. Prodrugs include, for example, compounds of this invention wherein hydroxy, amine or sulfhydryl groups are bonded to any group that, when administered to a patient, cleaves to form the hydroxy, amine or sulfhydryl groups. Thus,
30 representative examples of prodrugs include (but are not limited to) acetate, formate and benzoate derivatives of alcohol and amine functional groups of the compounds of

structure (I). Further, in the case of a carboxylic acid (-COOH), esters may be employed, such as methyl esters, ethyl esters, and the like.

In some instances, liposomes may be employed to facilitate uptake of the antisense oligonucleotide into cells. (See, e.g., Williams, S.A., *Leukemia* 10(12):1980-1989, 1996; Lappalainen et al., *Antiviral Res.* 23:119, 1994; Uhlmann et al., antisense oligonucleotides: a new therapeutic principle, *Chemical Reviews*, Volume 90, No. 4, pages 544-584, 1990; Gregoriadis, G., Chapter 14, *Liposomes, Drug Carriers in Biology and Medicine*, pp. 287-341, Academic Press, 1979). Hydrogels may also be used as vehicles for antisense oligomer administration, for example, as described in WO 93/01286. Alternatively, the oligonucleotides may be administered in microspheres or microparticles. (See, e.g., Wu, G.Y. and Wu, C.H., *J. Biol. Chem.* 262:4429-4432, 1987). Alternatively, the use of gas-filled microbubbles complexed with the antisense oligomers can enhance delivery to target tissues, as described in US Patent No. 6,245,747. Sustained release compositions may also be used. These may include semipermeable polymeric matrices in the form of shaped articles such as films or microcapsules.

In one embodiment, antisense inhibition is effective in treating a lymphocyte-related disease or conditions, by contacting lymphocytes, such as T cells, with an antisense agent described herein. The antisense agent is administered to a mammalian subject, e.g., human or domestic animal, in a suitable pharmaceutical carrier.

In one aspect of the method, the subject is a human subject, e.g., a patient diagnosed as having a lymphocyte-related disease or condition. The condition of a patient may also dictate prophylactic administration of an antisense oligomer of the invention, e.g. in the case of a patient who (1) is immunocompromised; (2) is a burn victim; (3) has an indwelling catheter; or (4) is about to undergo or has recently undergone surgery. In one preferred embodiment, the oligomer is a phosphorodiamidate morpholino oligomer, contained in a pharmaceutically acceptable carrier, and is delivered orally. In another preferred embodiment, the oligomer is a phosphorodiamidate morpholino oligomer, contained in a pharmaceutically acceptable carrier, and is delivered intravenously (i.v.).

In another application of the method, the subject is a livestock animal, e.g., a chicken, turkey, pig, cow, horse or goat, etc, and the treatment is either prophylactic or therapeutic.

In one embodiment, the antisense compound is administered in an amount and manner effective to result in a peak blood concentration of at least 200-400 nM antisense oligomer. Typically, one or more doses of antisense oligomer are administered, generally at regular intervals, for a period of about one to two weeks. Preferred doses for oral administration are from about 1-1000 mg oligomer per 70 kg. In some cases, doses of greater than 1000 mg oligomer/patient may be necessary. For i.v. administration, preferred doses are from about 0.5 mg to 1000 mg oligomer per 70 kg. The antisense oligomer may be administered at regular intervals for a short time period, e.g., daily for two weeks or less. However, in some cases the oligomer is administered intermittently over a longer period of time. Administration may be followed by, or concurrent with, administration of an antibiotic or other therapeutic treatment. The treatment regimen may be adjusted (dose, frequency, route, etc.) as indicated, based on the results of immunoassays, other biochemical tests and physiological examination of the subject under treatment.

An effective in vivo treatment regimen using the antisense oligonucleotides of the invention may vary according to the duration, dose, frequency and route of administration, as well as the condition of the subject under treatment. Accordingly, such in vivo therapy will often require monitoring by tests appropriate to the particular type of disease or condition under treatment, and corresponding adjustments in the dose or treatment regimen, in order to achieve an optimal therapeutic outcome. Treatment may be monitored, e.g., by general indicators of disease, such as complete blood count (CBC), nucleic acid detection methods, immunodiagnostic tests, or detection of heteroduplex.


The efficacy of an in vivo administered antisense oligomer of the invention in treating lymphocyte-related diseases and/or conditions may be determined from biological samples (tissue, blood, urine etc.) taken from a subject prior to, during and subsequent to administration of the antisense oligomer. Assays of such samples include (1) monitoring the presence or absence of heteroduplex formation with target

and non-target sequences, using procedures known to those skilled in the art, e.g., an electrophoretic gel mobility assay.

D. Preparation of the Oligomers

The morpholino subunits, the modified intersubunit linkages and
5 oligomers comprising the same can be prepared as described in the examples and in
U.S. Patent Nos. 5,185,444; 7,943, 762; 8,076,476; and 8,299,206 and co-pending U.S.
Application No. 13/118,298, which are hereby incorporated by reference in their
entirety. The morpholino subunits can be prepared according to the following general
Reaction Scheme I.

Reaction Scheme 1. Preparation of Morpholino Subunits



Referring to Reaction Scheme 1, wherein B represents a base pairing moiety and PG represents a protecting group, the morpholino subunits may be prepared from the corresponding ribonucleoside (1) as shown. The morpholino subunit (2) may be optionally protected by reaction with a suitable protecting group precursor, for example trityl chloride. The 3' protecting group is generally removed during solid-state oligomer synthesis as described in more detail below. The base pairing moiety may be suitably protected for solid-phase oligomer synthesis. Suitable protecting groups include benzoyl for adenine and cytosine, phenylacetyl for guanine, and pivaloyloxymethyl for hypoxanthine (I). The pivaloyloxymethyl group can be introduced onto the N1 position of the hypoxanthine heterocyclic base. Although an

unprotected hypoxanthine subunit, may be employed, yields in activation reactions are far superior when the base is protected. Other suitable protecting groups include those disclosed in U.S. Patent No. 8,076,476, which is hereby incorporated by reference in its entirety.

5 Reaction of **3** with the activated phosphorous compound **4a** or **4b** results in morpholino subunits having the desired linkage moiety (**5a** or **5b**). It should be noted that the R¹ and/or L¹ moieties may also be installed on the heterocyclic ring Z after formation of the P-C bond or even after the subunit has been incorporated into an oligomer.

10 Compounds of structure **4a** or **4b** can be prepared using any number of methods known to those of skill in the art, including those described in the examples. Coupling with the morpholino moiety then proceeds as outlined above.

 Compounds of structure **5a** or **5b** can be used in solid-phase automated oligomer synthesis for preparation of oligomers comprising the intersubunit linkages. Such methods are well known in the art. Briefly, a compound of structure **5a** or **5b** may be modified at the 5' end to contain a linker to a solid support. Once supported, the protecting group of **5a** or **5b** (e.g., trityl) is removed and the free amine is reacted with an activated phosphorous moiety of a second compound of structure **5** (or analogue thereof). This sequence is repeated until the desired length oligo is obtained. The
15 protecting group in the terminal 5' end may either be removed or left on if a 5'-
20 modification is desired. The oligo can be removed from the solid support using any number of methods, or example treatment with a base to cleave the linkage to the solid support.

 The preparation of modified morpholino subunits and morpholino
25 oligomers are described in more detail in the Examples. The morpholino oligomers containing any number of modified linkages may be prepared using methods described herein, methods known in the art and/or described by reference herein.

E. Antisense Targets of the Oligomers

 The present applicants have unexpectedly discovered that the described
30 oligomers (e.g., oligomers comprising gaunidinyl, alkylguanidinyl and/or alkylaminyl

substituents on one or more intersubunit linkage) are highly effective for delivery to lymphocytes, such as T cells. Accordingly, the described methods can be employed for treatment of any number of lymphocyte related diseases and/or conditions. In this regard, one of ordinary skill in the art will recognize the various diseases and/or conditions treatable with the oligomers and the associated target (e.g., gene sequence).

In general, the oligomers comprise a sequence targeted against a gene associated with a lymphocyte related disease or condition. Typical targeting sites within such genes include, but are not limited to start codons or splice junction sites, for example an ATG start codon region of an mRNA or a splice site of a pre-mRNA. Accordingly, certain oligomers of the invention comprise or consist of base sequences which specifically hybridize to such gene targets. In some embodiments, the oligomers have at least 90% sequence homology or at least 95% sequence homology, with the targeting site. Exemplary targets are provided in Table 1. Other targets are derivable by one of ordinary skill in the art.

15

Table 1. Exemplary Antisense Targets

Cell or Protein	Target	Function	Indication
T-Regulatory Cells	FoxP3	T regulatory cell transcription factor	Cancer
	PP1	Inhibitor of FoxP3	Autoimmune Disease
	Foxo1	Instrumental transcription factor for T regulatory cells	Cancer
PD-1	PD-1	Downregulates CD8 T cell activation	Cancer
	TRAF1	Inhibitor of PD-1 expression	Autoimmune Disease
CTLA-4	CTLA-4 SA2	Induces ligand independent CTLA-4 isoform	Autoimmune Disease

Cell or Protein	Target	Function	Indication
	CTLA-4 SA3	Induces soluble CTLA-4 isoform	Cancer
Th17	IL-17RC	Combines with IL-17RA to find IL-17A and IL-17F	Autoimmune Disease
	IL-17RA	Combines with IL-17RA to find IL-17A and IL-17F	Autoimmune Disease
	ROR γ	Th17 transcription factor	Autoimmune Disease
	IL-22	Promotes the homestasis of epithelia and is involved in early host defense against microbial pathogens	Autoimmune Disease (Psoriasis & Brain Inflammation)

This description is not meant to limit the invention in any way but serves to exemplify the range of human and animal disease conditions that can be addressed using oligomers comprising the modified intersubunit linkages described herein.

EXAMPLES


Unless otherwise noted, all chemicals were obtained from Sigma-Aldrich-Fluka. Benzoyl adenosine, benzoyl cytidine, and phenylacetyl guanosine were obtained from Carbosynth Limited, UK.

5 Synthesis of PMO and PMO containing further linkage modifications as described herein was done using methods known in the art and described in pending U.S. applications Nos. 12/271,036 and 12/271,040 and PCT publication number WO/2009/064471, which are hereby incorporated by reference in their entirety.

10 PMO with a 3' trityl modification are synthesized essentially as described in PCT publication number WO/2009/064471 with the exception that the detritylation step is omitted.

EXAMPLE 1


TERT-BUTYL 4-(2,2,2-TRIFLUOROACETAMIDO)PIPERIDINE-1-CARBOXYLATE



15 To a suspension of *tert*-butyl 4-aminopiperidine-1-carboxylate (48.7 g, 0.243 mol) and DIPEA (130 mL, 0.749 mol) in DCM (250 mL) was added ethyl trifluoroacetate (35.6 mL, 0.300 mol) dropwise while stirring. After 20 hours, the solution was washed with citric acid solution (200 mL x 3, 10 % *w/v aq*) and sodium bicarbonate solution (200 mL x 3, *conc aq*), dried (MgSO₄), and filtered through silica
20 (24 g). The silica was washed with DCM and the combined eluant was partially concentrated (100 mL), and used directly in the next step. APCI/MS calcd. for C₁₂H₁₉F₃N₂O₃ 296.1, found *m/z* = 294.9 (M-1).

EXAMPLE 2

2,2,2-TRIFLUORO-N-(PIPERIDIN-4-YL)ACETAMIDE HYDROCHLORIDE




To a stirred DCM solution of the title compound of Example 1 (100 mL)
 5 was added dropwise a solution of hydrogen chloride (250 mL, 1.0 mol) in 1,4-dioxane
 (4 M). Stirring was continued for 6 hours, then the suspension was filtered, and the
 solid washed with diethyl ether (500 mL) to afford the title compound (54.2 g, 96%
 yield) as a white solid. APCI/MS calcd. for C₇H₁₁F₃N₂O 196.1, found *m/z* = 196.9
 (M+1).

10

EXAMPLE 3


(4-(2,2,2-TRIFLUOROACETAMIDO)PIPERIDIN-1-YL)PHOSPHONIC DICHLORIDE



To a cooled (ice/water bath) suspension of the title compound of
 Example 2 (54.2 g, 0.233 mol) in DCM (250 mL) was added dropwise phosphorus
 15 oxychloride (23.9 mL, 0.256 mol) and DIPEA (121.7 mL, 0.699 mol) and stirred. After
 15 minutes, the bath was removed and with continued stirring the mixture allowed to
 warm to ambient temperature. After 1 hour, the mixture was partially concentrated
 (100 mL), the suspension filtered, and the solid washed with diethyl ether to afford the
 title compound (43.8 g, 60% yield) as a white solid. The eluant was partially
 20 concentrated (100 mL), the resulting suspension filtered, and the solid washed with
 diethyl ether to afford additional title compound (6.5 g, 9% yield). ESI/MS calcd. for
 1-(4-nitrophenyl)piperazine derivative C₁₇H₂₂ClF₃N₅O₄P 483.1, found *m/z* = 482.1 (M-
 1).

EXAMPLE 4

((2S,6S)-6-((R)-5-METHYL-2,6-DIOXO-1,2,3,6-TETRAHYDROPYRIDIN-3-YL)-4-TRITYLMORPHOLIN-2-YL)METHYL (4-(2,2,2-TRIFLUOROACETAMIDO)PIPERIDIN-1-YL)PHOSPHONOCHLORIDATE




5

To a stirred, cooled (ice/water bath) solution of the title compound of Example 3 (29.2 g, 93.3 mmol) in DCM (100 mL) was added dropwise over 10 minutes a DCM solution (100 mL) of Mo(Tr)T # (22.6 g, 46.7 mmol), 2,6-Lutidine (21.7 mL, 187 mmol), and 4-(dimethylamino)pyridine (1.14 g, 9.33 mmol). The bath was allowed to warm to ambient temperature. After 15 hours, the solution was washed with a citric acid solution (200 mL x 3, 10 % w/v aq), dried (MgSO₄), concentrated, and the crude oil was loaded directly onto column. Chromatography [SiO₂ column (120 g), hexanes/EtOAc eluant (gradient 1:1 to 0:1), repeated x 3] fractions were concentrated to provide the title compound (27.2 g, 77% yield) as a white solid. ESI/MS calcd. for the 1-(4-nitrophenyl)piperazine derivative C₄₆H₅₀F₃N₈O₈P 930.3, found *m/z* = 929.5 (M-1).

15

EXAMPLE 5

((2S,6R)-6-(6-BENZAMIDO-9H-PURIN-9-YL)-4-TRITYLMORPHOLIN-2-YL)METHYL (4-(2,2,2-TRIFLUOROACETAMIDO)PIPERIDIN-1-YL)PHOSPHONOCHLORIDATE



20

The title compound was synthesized in a manner analogous to that described in Example 4 to afford the title compound (15.4 g, 66% yield) as a white

solid. ESI/MS calcd. for 1-(4-nitrophenyl)piperazine derivative $C_{53}H_{53}F_3N_{11}O_7P$
1043.4, found $m/z = 1042.5$ (M-1).

EXAMPLE 6

GLOBAL GUANIDINYLATION OF OLIGOMERS

5 An appropriate amount of an oligomer containing an aminopiperidine
linkage (or methylated analogue thereof) prepared as described above (25 mg, 2.8
 μmol) was weighed into a vial (6 ml). 1H-Pyrozole-1-carboxamidinium chloride (15 mg,
102 μmol) and potassium carbonate (20 mg, 0.15 mmol) were added to the vial. Water
was added (500 μl), and the reaction mixture was stirred at room temperature overnight
10 (about 18 hours). Reaction completion was determined by MALDI.

 Once complete, the reaction was diluted with 1% ammonia in water (10
ml) and loaded on to an SPE column (2 cm). The vial was rinsed with 1% ammonia
solution (2X 2ml), and the SPE column was washed with 1% ammonia in water (3X
6ml). Product was eluted with 45% acetonitrile in 1% ammonia in water (6 ml).
15 Fractions containing oligomer were identified by UV optical density measurement.
Product was isolated by lyophilization. Purity and identity were determined by MALDI
and HPLC (C-18 and/or SAX).

EXAMPLE 7

PREPARATION OF MORPHOLINO OLIGOMERS

20 Preparation of trityl piperazine phenyl carbamate 35 (see Figure 3): To a
cooled suspension of compound 11 in dichloromethane (6 mL/g 11) was added a
solution of potassium carbonate (3.2 eq) in water (4 mL/g potassium carbonate). To
this two-phase mixture was slowly added a solution of phenyl chloroformate (1.03 eq)
in dichloromethane (2 g/g phenyl chloroformate). The reaction mixture was warmed to
25 20 °C. Upon reaction completion (1-2 hr), the layers were separated. The organic layer
was washed with water, and dried over anhydrous potassium carbonate. The product 35
was isolated by crystallization from acetonitrile. Yield = 80%

 Preparation of carbamate alcohol 36: Sodium hydride (1.2 eq) was
suspended in 1-methyl-2-pyrrolidinone (32 mL/g sodium hydride). To this suspension

were added triethylene glycol (10.0 eq) and compound 35 (1.0 eq). The resulting slurry was heated to 95 °C. Upon reaction completion (1-2 hr), the mixture was cooled to 20 °C. To this mixture was added 30% dichloromethane/methyl tert-butyl ether (v:v) and water. The product-containing organic layer was washed successively with aqueous NaOH, aqueous succinic acid, and saturated aqueous sodium chloride. The product 36 was isolated by crystallization from dichloromethane/methyl tert-butyl ether/heptane. Yield = 90%.

Preparation of Tail acid 37: To a solution of compound 36 in tetrahydrofuran (7 mL/g 36) was added succinic anhydride (2.0 eq) and DMAP (0.5 eq). The mixture was heated to 50 °C. Upon reaction completion (5 hr), the mixture was cooled to 20 °C and adjusted to pH 8.5 with aqueous NaHCO₃. Methyl tert-butyl ether was added, and the product was extracted into the aqueous layer. Dichloromethane was added, and the mixture was adjusted to pH 3 with aqueous citric acid. The product-containing organic layer was washed with a mixture of pH=3 citrate buffer and saturated aqueous sodium chloride. This dichloromethane solution of 37 was used without isolation in the preparation of compound 38.

Preparation of 38: To the solution of compound 37 was added N-hydroxy-5-norbornene-2,3-dicarboxylic acid imide (HONB) (1.02 eq), 4-dimethylaminopyridine (DMAP) (0.34 eq), and then 1-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC) (1.1 eq). The mixture was heated to 55 °C. Upon reaction completion (4-5 hr), the mixture was cooled to 20 °C and washed successively with 1:1 0.2 M citric acid/brine and brine. The dichloromethane solution underwent solvent exchange to acetone and then to N,N-dimethylformamide, and the product was isolated by precipitation from acetone/ N,N-dimethylformamide into saturated aqueous sodium chloride. The crude product was reslurried several times in water to remove residual N,N-dimethylformamide and salts. Yield = 70% of 38 from compound 36. Introduction of the activated "Tail" onto the disulfide anchor-resin was performed in NMP by the procedure used for incorporation of the subunits during solid phase synthesis.

Preparation of the Solid Support for Synthesis of Morpholino Oligomers: This procedure was performed in a silanized, jacketed peptide vessel (custom made by

ChemGlass, NJ, USA) with a coarse porosity (40-60 μm) glass frit, overhead stirrer, and 3-way Teflon stopcock to allow N_2 to bubble up through the frit or a vacuum extraction. Temperature control was achieved in the reaction vessel by a circulating water bath.

5 The resin treatment/wash steps in the following procedure consist of two basic operations: resin fluidization and solvent/solution extraction. For resin fluidization, the stopcock was positioned to allow N_2 flow up through the frit and the specified resin treatment/wash was added to the reactor and allowed to permeate and completely wet the resin. Mixing was then started and the resin slurry mixed for the
10 specified time. For solvent/solution extraction, mixing and N_2 flow were stopped and the vacuum pump was started and then the stopcock was positioned to allow evacuation of resin treatment/wash to waste. All resin treatment/wash volumes were 15 mL/g of resin unless noted otherwise.

To aminomethylpolystyrene resin (100-200 mesh; ~ 1.0 mmol/g N_2
15 substitution; 75 g, 1 eq, Polymer Labs, UK, part #1464-X799) in a silanized, jacketed peptide vessel was added 1-methyl-2-pyrrolidinone (NMP; 20 ml/g resin) and the resin was allowed to swell with mixing for 1-2 hr. Following evacuation of the swell solvent, the resin was washed with dichloromethane (2 x 1-2 min), 5% diisopropylethylamine in 25% isopropanol/dichloromethane (2 x 3-4 min) and dichloromethane (2 x 1-2 min).
20 After evacuation of the final wash, the resin was fluidized with a solution of disulfide anchor 34 in 1-methyl-2-pyrrolidinone (0.17 M; 15 mL/g resin, ~ 2.5 eq) and the resin/reagent mixture was heated at 45 $^\circ\text{C}$ for 60 hr. On reaction completion, heating was discontinued and the anchor solution was evacuated and the resin washed with 1-methyl-2-pyrrolidinone (4 x 3-4 min) and dichloromethane (6 x 1-2 min). The resin
25 was treated with a solution of 10% (v/v) diethyl dicarbonate in dichloromethane (16 mL/g; 2 x 5-6 min) and then washed with dichloromethane (6 x 1-2 min). The resin 39 (see Figure 4) was dried under a N_2 stream for 1-3 hr and then under vacuum to constant weight ($\pm 2\%$). Yield: 110-150% of the original resin weight.

Determination of the Loading of Aminomethylpolystyrene-disulfide
30 resin: The loading of the resin (number of potentially available reactive sites) is

determined by a spectrometric assay for the number of triphenylmethyl (trityl) groups per gram of resin.

A known weight of dried resin (25 ± 3 mg) is transferred to a silanized 25 ml volumetric flask and ~5 mL of 2% (v/v) trifluoroacetic acid in dichloromethane is added. The contents are mixed by gentle swirling and then allowed to stand for 30 min. The volume is brought up to 25 mL with additional 2% (v/v) trifluoroacetic acid in dichloromethane and the contents thoroughly mixed. Using a positive displacement pipette, an aliquot of the trityl-containing solution (500 μ L) is transferred to a 10 mL volumetric flask and the volume brought up to 10 mL with methanesulfonic acid.

The trityl cation content in the final solution is measured by UV absorbance at 431.7 nm and the resin loading calculated in trityl groups per gram resin (μ mol/g) using the appropriate volumes, dilutions, extinction coefficient (ϵ : 41 μ mol⁻¹cm⁻¹) and resin weight. The assay is performed in triplicate and an average loading calculated.

The resin loading procedure in this example will provide resin with a loading of approximately 500 μ mol/g. A loading of 300-400 in μ mol/g was obtained if the disulfide anchor incorporation step is performed for 24 hr at room temperature.

Tail loading: Using the same setup and volumes as for the preparation of aminomethylpolystyrene-disulfide resin, the Tail can be introduced into the molecule. For the coupling step, a solution of 38 (0.2 M) in NMP containing 4-ethylmorpholine (NEM, 0.4 M) was used instead of the disulfide anchor solution. After 2 hr at 45 °C, the resin 39 was washed twice with 5% diisopropylethylamine in 25% isopropanol/dichloromethane and once with DCM. To the resin was added a solution of benzoic anhydride (0.4 M) and NEM (0.4 M). After 25 min, the reactor jacket was cooled to room temperature, and the resin washed twice with 5% diisopropylethylamine in 25% isopropanol/dichloromethane and eight times with DCM. The resin 40 was filtered and dried under high vacuum. The loading for resin 40 is defined to be the loading of the original aminomethylpolystyrene-disulfide resin 39 used in the Tail loading.

Solid Phase Synthesis: Morpholino Oligomers were prepared on a Gilson AMS-422 Automated Peptide Synthesizer in 2 mL Gilson polypropylene

reaction columns (Part # 3980270). An aluminum block with channels for water flow was placed around the columns as they sat on the synthesizer. The AMS-422 will alternatively add reagent/wash solutions, hold for a specified time, and evacuate the columns using vacuum.

5 For oligomers in the range up to about 25 subunits in length, aminomethylpolystyrene-disulfide resin with loading near 500 μmol/g of resin is preferred. For larger oligomers, aminomethylpolystyrene-disulfide resin with loading of 300-400 μmol/g of resin is preferred. If a molecule with 5'-Tail is desired, resin that has been loaded with Tail is chosen with the same loading guidelines.

10 The following reagent solutions were prepared:

Detritylation Solution: 10% Cyanoacetic Acid (w/v) in 4:1 dichloromethane/acetonitrile; Neutralization Solution: 5% Diisopropylethylamine in 3:1 dichloromethane/isopropanol; Coupling Solution: 0.18 M (or 0.24 M for oligomers having grown longer than 20 subunits) activated Morpholino Subunit of the desired
 15 base and linkage type and 0.4 M N ethylmorpholine, in 1,3-dimethylimidazolidinone. Dichloromethane (DCM) was used as a transitional wash separating the different reagent solution washes.

On the synthesizer, with the block set to 42 °C, to each column containing 30 mg of aminomethylpolystyrene-disulfide resin (or Tail resin) was added 2
 20 mL of 1-methyl-2-pyrrolidinone and allowed to sit at room temperature for 30 min. After washing with 2 times 2 mL of dichloromethane, the following synthesis cycle was employed:

	Step	Volume	Delivery	Hold time
	Detritylation	1.5 mL	Manifold	15 seconds
25	Detritylation	1.5 mL	Manifold	15 seconds
	Detritylation	1.5 mL	Manifold	15 seconds
	Detritylation	1.5 mL	Manifold	15 seconds
	Detritylation	1.5 mL	Manifold	15 seconds
	Detritylation	1.5 mL	Manifold	15 seconds
30	Detritylation	1.5 mL	Manifold	15 seconds
	DCM	1.5 mL	Manifold	30 seconds

	Neutralization	1.5 mL	Manifold	30 seconds
	Neutralization	1.5 mL	Manifold	30 seconds
	Neutralization	1.5 mL	Manifold	30 seconds
	Neutralization	1.5 mL	Manifold	30 seconds
5	Neutralization	1.5 mL	Manifold	30 seconds
	Neutralization	1.5 mL	Manifold	30 seconds
	DCM	1.5 mL	Manifold	30 seconds
	Coupling	350 uL – 500 uL	Syringe	40 minutes
	DCM	1.5 mL	Manifold	30 seconds
10	Neutralization	1.5 mL	Manifold	30 seconds
	Neutralization	1.5 mL	Manifold	30 seconds
	DCM	1.5 mL	Manifold	30 seconds
	DCM	1.5 mL	Manifold	30 seconds
	DCM	1.5 mL	Manifold	30 seconds
15				

The sequences of the individual oligomers were programmed into the synthesizer so that each column receives the proper coupling solution (A,C,G,T,I) in the proper sequence. When the oligomer in a column had completed incorporation of its final subunit, the column was removed from the block and a final cycle performed manually with a coupling solution comprised of 4-methoxytriphenylmethyl chloride (0.32 M in DMI) containing 0.89 M 4-ethylmorpholine.

Cleavage from the resin and removal of bases and backbone protecting groups: After methoxytritylation, the resin was washed 8 times with 2 mL 1-methyl-2-pyrrolidinone. One mL of a cleavage solution consisting of 0.1 M 1,4-dithiothreitol (DTT) and 0.73 M triethylamine in 1-methyl-2-pyrrolidinone was added, the column capped, and allowed to sit at room temperature for 30 min. After that time, the solution was drained into a 12 mL Wheaton vial. The greatly shrunken resin was washed twice with 300 μ L of cleavage solution. To the solution was added 4.0 mL conc aqueous ammonia (stored at -20 °C), the vial capped tightly (with Teflon lined screw cap), and the mixture swirled to mix the solution. The vial was placed in a 45 °C oven for 16-24 hr to effect cleavage of base and backbone protecting groups.

Initial Oligomer Isolation: The vialled ammonolysis solution was removed from the oven and allowed to cool to room temperature. The solution was diluted with 20 mL of 0.28% aqueous ammonia and passed through a 2.5x10 cm column containing Macroprep HQ resin (BioRad). A salt gradient (A: 0.28% ammonia with B: 1 M sodium chloride in 0.28% ammonia; 0-100% B in 60 min) was used to elute the methoxytrityl containing peak. The combined fractions were pooled and further processed depending on the desired product.

Demethoxytritylation of Morpholino Oligomers: The pooled fractions from the Macroprep purification were treated with 1 M H₃PO₄ to lower the pH to 2.5. After initial mixing, the samples sat at room temperature for 4 min, at which time they are neutralized to pH 10-11 with 2.8% ammonia/water. The products were purified by solid phase extraction (SPE).

Amberchrome CG-300M (Rohm and Haas; Philadelphia, PA) (3 mL) is packed into 20 mL fritted columns (BioRad Econo-Pac Chromatography Columns (732-1011)) and the resin rinsed with 3 mL of the following: 0.28% NH₄OH/80% acetonitrile; 0.5M NaOH/20% ethanol; water; 50 mM H₃PO₄/80% acetonitrile; water; 0.5 NaOH/20% ethanol; water; 0.28% NH₄OH.

The solution from the demethoxytritylation was loaded onto the column and the resin rinsed three times with 3-6 mL 0.28% aqueous ammonia. A Wheaton vial (12 mL) was placed under the column and the product eluted by two washes with 2 mL of 45% acetonitrile in 0.28% aqueous ammonia. The solutions were frozen in dry ice and the vials placed in a freeze dryer to produce a fluffy white powder. The samples were dissolved in water, filtered through a 0.22 micron filter (Pall Life Sciences, Acrodisc 25 mm syringe filter, with a 0.2 micron HT Tuffryn membrane) using a syringe and the Optical Density (OD) was measured on a UV spectrophotometer to determine the OD units of oligomer present, as well as dispense sample for analysis. The solutions were then placed back in Wheaton vials for lyophilization.

Analysis of Morpholino Oligomers: MALDI-TOF mass spectrometry was used to determine the composition of fractions in purifications as well as provide evidence for identity (molecular weight) of the oligomers. Samples were run following dilution with solution of 3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic acid), 3,4,5-

trihydroxyacetophenone (THAP) or alpha-cyano-4-hydroxycinnamic acid (HCCA) as matrices.

Cation exchange (SCX) HPLC was performed using a Dionex ProPac SCX-10, 4x250mm column (Dionex Corporation; Sunnyvale, CA) using 25 mM pH=5 sodium acetate 25% acetonitrile (Buffer A) and 25 mM pH=5 sodium acetate 25% acetonitrile 1.5 M potassium chloride (buffer B) (Gradient 10-100% B in 15 min) or 25 mM KH₂PO₄ 25% acetonitrile at pH=3.5 (buffer A) and 25 mM KH₂PO₄ 25% acetonitrile at pH=3.5 with 1.5 M potassium chloride (buffer B) (Gradient 0-35% B in 15 min). The former system was used for positively charged oligomers that do not have a peptide attached, while the latter was used for peptide conjugates.

Purification of Morpholino Oligomers by Cation Exchange Chromatography: The sample is dissolved in 20 mM sodium acetate, pH=4.5 (buffer A) and applied to a column of Source 30 cation exchange resin (GE Healthcare) and eluted with a gradient of 0.5 M sodium chloride in 20 mM sodium acetate and 40% acetonitrile, pH=4.5 (buffer B). The pooled fractions containing product are neutralized with conc aqueous ammonia and applied to an Amberchrome SPE column. The product is eluted, frozen, and lyophilized as above.

EXAMPLE 8

IN VITRO AND IN VIVO TESTING OF THE OLIGOMERS

A PMO (5'-GCT ATT ACC TTA ACC CAG-3'; SEQ ID NO: 1) designed to restore correct splicing in the enhanced green fluorescent protein (EGFP) gene was modified at the intersubunit linkage and/or the 5' and/or 3' end to produce modified PMOs, which were evaluated for their splice-correction activity and tissue distribution in the EGFP-654 transgenic mouse model (Sazani, Gemignani *et al.* 2002). In this model, the EGFP-654 gene encoding for functional EGFP is interrupted by an aberrantly-spliced mutated intron, and cellular uptake of EGFP targeted PMOs, such as SEQ ID NO: 1, can be evaluated by RT-PCR detection of the restored EGFP-654 splice product in tissues or detection of functional EGFP by fluorescence.

Sequences of the oligomers employed for the experiments described herein are presented in Table 2. The oligomers typically comprise a piperazine linker




on the 5' end and either an ethylene glycol trimer (EG3) or guanidiny terminal group linked thereto. The 3' end is either unmodified (H) or comprises a trityl, guanidiny or peptide moiety. An "*" indicates the presence of a modified intersubunit linkage, the structure of which is provided in Table 3. All other linkages are PMO.




5

Table 2. Oligomer Sequences

Number	Sequence	Modifications	3' End	5' End
0-1-0-730	GCT ATT ACC TTA ACC CAG (SEQ ID NO: 2)	None	H	EG3
NG-10-0389	GC*T AT*T ACC T*TA ACC CAG (SEQ ID NO: 3)	*=G-pip	Trityl	Guanidine
NG-12-0127	GC*T A*T*T ACC T*TA ACC CAG (SEQ ID NO: 4)	*=map	H	EG3
NG-12-0128	GC*T A*T*T ACC *T*TA ACC CAG (SEQ ID NO: 5)	*=map	H	EG3
NG-12-0153	*G*C*T *A*T*T *A*C*C *T*T*A *A*C*C *C*A*G (SEQ ID NO: 6)	*=morph	H	EG3
NG-12-0157	GC*T A*T*T ACC T*TA ACC CAG (SEQ ID NO: 7)	*=MG-pip	C=(NH)NH ₂	EG3
NG-12-0158	GC*T A*T*T ACC *T*TA ACC CAG (SEQ ID NO: 8)	*=MG-pip	C=(NH)NH ₂	EG3
NG-08-0524	GCT ATT ACC TTA ACC CAG (SEQ ID NO: 9)	3'-peptide	(RXRRBR) ₂ -XB	EG3
NG-11-0153	GCT ATT ACC TTA ACC CAG (SEQ ID NO: 10)	3'-peptide	R ₆ -G	EG3
NG-10-0110	GC*T AT*T ACC T*TA ACC CAG (SEQ ID NO: 11)	*=guanidiny	Guanidiny	EG3
NG-10-0299	GC*T AT*T ACC T*TA ACC CAG (SEQ ID NO: 12)	*=apn	H	EG3

Table 3. Structure of Intersubunit Linkages

Name	Structure
G-pip	
Map	
MG-pip	

Name	Structure
Apn	
Morph	
PMO	

Tissue Distribution

5 EGFP-654 transgenic mice (14-28 weeks old, female) were injected by tail vein I.V. with a G-pip modified oligomer (NG-10-0389) or a peptide-modified oligomer (NG-08-0524, X = aminohexanoic acid, B = beta-alanine) at doses of 2.5 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg (PBS vehicle). Tissues were harvested 7 days post injection and analyzed for presence of the oligomers. Figure 1 presents the tissue distribution data for the 10mg/kg dose. The data show that the G-pip modified oligomer has a higher affinity for T-cells relative to the peptide modified oligomer.

10

In vitro delivery to lymphocytes

Splenocytes from an EGFP-654 reporter mouse were harvested and a cell suspension was made. Cells were CD3/CD28 stimulated in the presence of the oligomers from Table 2 for 24h at 37 °C. Cells were harvested from the plate and run through a flow cytometer for detection of EGFP and T and B cell markers. Activated and resting T cells were delineated using CD25 as the activation marker. Successful

15

delivery to T cells is indicated by the presence of EGFP within the cell (*i.e.*, EGFP positive cells).

Figures 2-6 show the frequency of EGFP positive cells within each lymphocyte population for the oligomers from Table 2. Figures 2 and 3 present data for activated T cells and B cells, respectively. The data indicate that intersubunit linkages containing guanidinyl, alkylguanidinyl or alkylaminyl groups have higher efficacy in T cells and B cells relative to unmodified PMO (dimethylamine linkages) and morpholino PMO (morpholino linkages).

Figures 4, 5 and 6 present data for activated T cells, resting T cells and B cells, respectively. This data shows that oligomers having guanidinyl modifications in the intersubunit linkages having higher efficacy in T and B cells relative to peptide conjugated oligomers, especially at lower concentrations.

In vivo delivery to lymphocytes

EGFP-654 reporter mice were injected with various oligomers from Table 2 as described above. Splenocytes were harvested 7 days-post injection and stained for T regulatory markers and EGFP fluorescence. The frequency of EGFP positive cells in the oligomer treated cohort was divided by the frequency of EGFP positive cells in saline treated mice to generate the fold increase in EGFP over vehicle. Results are presented in Figures 7-10. Again, the data indicate that intersubunit linkages containing guanidinyl, alkylguanidinyl or alkylaminyl groups have higher efficacy in T cells and macrophages relative to unmodified PMO (dimethylamine linkages) and other types of PMO modifications (e.g. peptide).


The various embodiments described above can be combined to provide further embodiments. All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification and/or listed in the Application Data Sheet, including but not limited to U.S. Provisional Patent Application No. 62/171,102 filed on June 4, 2015, are incorporated herein by reference, in their entirety. Aspects of the

embodiments can be modified, if necessary to employ concepts of the various patents, applications and publications to provide yet further embodiments.

5 These and other changes can be made to the embodiments in light of the above-detailed description. In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and the claims, but should be construed to include all possible embodiments along with the full scope of equivalents to which such claims are entitled. Accordingly, the claims are not limited by the disclosure.

CLAIMS

1. A method for treatment of a lymphocyte-related disease or condition, the method comprising administering an effective amount of an oligomer to a patient in need thereof, wherein the oligomer comprises a backbone having a sequence of morpholino ring structures joined by intersubunit linkages, the intersubunit linkages joining a 3'-end of one morpholino ring structure to a 5'-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing moiety, such that the oligomer can bind in a sequence-specific manner to a target nucleic acid, wherein at least one of the intersubunit linkages has the following structure (I):



(I)

or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein:

R^1 is guanidinylyl, alkylguanidinylyl or alkylaminylyl;


L^1 is absent or present, and when present is selected from alkylene, aminoalkylene, oxyalkylene and thioalkylene;

X is, at each occurrence, independently S or O;

Y is, at each occurrence, independently -O- or -NH-; and

Z is an optionally substituted 5, 6 or 7-membered heterocyclic ring.

2. The method of claim 1, wherein the morpholino ring structures have the following structure (i):



(i)


wherein B is, at each occurrence, independently a base-pairing moiety.

3. The method of any one of claims 1-2, wherein Z is an optionally substituted 5 or 6-membered heterocyclic ring.


4. The method of claim 3, wherein Z is pyrrolidinyl, or piperidinyl.

5. The method of claim 4, wherein Z is piperidinyl.


6. The method of claim 4, wherein Z has one of the following structures:



7. The method of claim 6, wherein Z has the following structure:




8. The method of claim 7, wherein Z has the following structure:



9. The method of any one of claims 1-8, wherein R¹ is guanidinyl.

10. The method of any one of claims 1-8, wherein R¹ is alkylguanidinyl.

11. The method of claim 10, wherein alkylguanidinyl has the following structure:



wherein R' is C₁-C₆alkyl.

12. The method of claim 11, wherein R' is methyl.

13. The method of any one of claims 1-8, wherein R¹ is alkylaminyl.

14. The method of claim 13, wherein alkylaminyl is -NHR'', where R'' is C₁-C₆alkyl.


15. The method of claim 14, wherein R'' is methyl.

16. The method of any one of claim 1-15, wherein L¹ is absent.

17. The method of any one of claims 1-16, wherein X is O.

18. The method of any one of claims 1-17, wherein Y is -O-.

19. The method of any one of claims 1-13, wherein at least one of the intersubunit linkages has the following structure (II):



(II)

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:

R^2 and R^3 are each independently H or C_1 - C_6 alkyl,

X' is S or O; and


Y' is $-O-$ or $-NH-$.

20. The method of claim 19, wherein R^2 and R^3 are each methyl.


21. The method of claim 19 or 20 wherein X' is O.

22. The method of any one of claims 19-21, wherein Y' is $-O-$.


23. The method of claim 1, wherein at least one of the intersubunit linkages has the following structure:



24. The method of claim 1, wherein at least one of the intersubunit linkages has the following structure:



25. The method of claim 1, wherein at least one of the intersubunit linkages has the following structure:




26. The method of any one of claims 1-25, wherein the lymphocyte-related disease or condition is a T-cell-related disease or condition.

27. The method of claim 26, wherein the T-cell is an activated T-cell.

28. The method of claim 26, wherein the T-cell is a CD4 or CD8 cell.

29. The method of any one of claims 1-28, wherein the disease or condition is cancer or an autoimmune disease or condition.

30. A method for treatment of a T-cell related disease or condition, the method comprising contacting activated T-cells with an oligomer comprising a backbone having a sequence of morpholino ring structures joined by intersubunit linkages, the intersubunit linkages joining a 3'-end of one morpholino ring structure to a 5'-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing moiety, such that the oligomer can bind in a sequence-specific manner to a target nucleic acid, wherein at least one of the intersubunit linkages has the following structure (I):



(I)

or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein:

R^1 is guanidinyl, alkylguanidinyl or alkylaminyl;


L^1 is absent or present, and when present is selected from alkylene, aminoalkylene, oxyalkylene, oxoalkylene and thioalkylene;

X is, at each occurrence, independently S or O;

Y is, at each occurrence, independently $-O-$ or $-NH-$; and

Z is an optionally substituted 5, 6 or 7-membered heterocyclic ring.

31. Use of an oligomer comprising a backbone having a sequence of morpholino ring structures joined by intersubunit linkages, the intersubunit linkages joining a 3'-end of one morpholino ring structure to a 5'-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing moiety, such that the oligomer can bind in a sequence-specific manner to a target nucleic acid, wherein at least one of the intersubunit linkages has the following structure (I):



(I)

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:

R^1 is guanidinyl, alkylguanidinyl or alkylaminyl;

L^1 is absent or present, and when present is selected from alkylene, aminoalkylene, oxyalkylene, oxoalkylene and thioalkylene;

X is, at each occurrence, independently S or O;

Y is, at each occurrence, independently $-O-$ or $-NH-$; and

Z is an optionally substituted 5, 6 or 7-membered heterocyclic ring,

for preparation of a pharmaceutical composition for treatment of a lymphocyte-related disease or condition.

Figure 1





Figure 2



2 / 5

Figure 3





Figure 4



3 / 5

Figure 5




Figure 6




Figure 7

EGFP+ Activated T Reg. cells as measured by flow cytometry




Figure 8

EGFP+ Resting T Reg. cells as measured by flow cytometry




Figure 9





Figure 10



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2016/035671

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61K 31/5377; A61K 31/675; C07D 413/14; C12N 15/113 (2016.01)

CPC - A61K 31/5377; C07F 9/65616; C12N 15/113; C12N 2310/315; C12N 2310/3231 (2016.08)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC - A61K 31/5377; A61K 31/675; C07D 413/14; C12N 15/113

CPC - A61K 31/5377; C07F 9/65616; C12N 15/113; C12N 2310/315; C12N 2310/3231; C12N 2310/3233

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

USPC - 514/231.2; 514/231.5; 514/231.8; 514/232.2; 536/24.5; 536/24.1; IPC - A61K 31/5377; A61K 31/675; C07D 413/14; C12N 15/113; CPC - A61K 31/5377; C07F 9/65616; C12N 15/113; C12N 2310/315; C12N 2310/3231; C12N 2310/3233 (keyword delimited)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Orbit, Google Patents, Google, PubChem, SureChem, STN

Search terms used: Oligonucleotide, morpholine, morpholino, guanidine, pyrrolidine, intersubunit linkage, base pair

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DEVI et al.: In vivo Bioavailability and Pharmacokinetics of a c-MYC Antisense Phosphorodiamidate Morpholino Oligomer, AVI-4126, in Solid Tumors. Clin. Cancer Res.;11 (10); 3930-3938; 15 May 2005. [retrieved on 27.07.2016]. Retrieved from the Internet. <URL: http://clincancerres.aacrjournals.org/content/11/10/3930.full-text.pdf >. entire document	1-4, 30, 31
A	US 8,697,858 B2 (IVERSEN) 15 April 2014 (15.04.2014) entire document	1-4, 30, 31
A	US 2011/0166082 A1 (IVERSEN et al) 07 July 2011 (07.07.2011) entire document	1-4, 30, 31
A	US 2011/0318382 A1 (MOURICH et al) 29 December 2011 (29.12.2011) entire document	1-4, 30, 31

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

23 September 2016

Date of mailing of the international search report

13 OCT 2016

Name and mailing address of the ISA/

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents

P.O. Box 1450, Alexandria, VA 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Blaine R. Copenheaver

PCT Helpdesk: 571-272-4300

PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2016/035671

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.: 9-22, 26-29
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See Extra Sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-4, 30, 31

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

Continued from Box No. III Observations where unity of invention is lacking

Claims 1-4, 30, and 31 have been analyzed subject to the restriction that claims read on a method for treatment of a lymphocyte-related disease or condition, the method comprising administering an effective amount of an oligomer to a patient in need thereof, wherein the oligomer comprises a backbone having a sequence of morpholino ring structures joined by intersubunit linkages, the intersubunit linkages joining a 3'-end of one morpholino ring structure to a 5'-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing moiety, such that the oligomer can bind in a sequence-specific manner to a target nucleic acid, wherein at least one of the intersubunit linkages has the structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1 is guanidiny, L1 is absent, X is, at each occurrence, independently S, Y is, at each occurrence, independently -O-, and Z is an unsubstituted 5-membered heterocyclic ring, which is pyrrolidiny, and wherein the morpholino ring structures are connected to the intersubunit linkages and base-pairing moieties as shown in claim 2; and methods and uses thereof

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees need to be paid.

Group I+: claims 1-7, 23-25, 30, and 31 are drawn to methods and uses of an oligomer comprising a backbone having a sequence of morpholino ring structures joined by intersubunit linkages.

The first invention of Group I+ is restricted to a method for treatment of a lymphocyte-related disease or condition, the method comprising administering an effective amount of an oligomer to a patient in need thereof, wherein the oligomer comprises a backbone having a sequence of morpholino ring structures joined by intersubunit linkages, the intersubunit linkages joining a 3'-end of one morpholino ring structure to a 5'-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing moiety, such that the oligomer can bind in a sequence-specific manner to a target nucleic acid, wherein at least one of the intersubunit linkages has the structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1 is guanidiny, L1 is absent, X is, at each occurrence, independently S, Y is, at each occurrence, independently -O-, and Z is an unsubstituted 5-membered heterocyclic ring, which is pyrrolidiny, and wherein the morpholino ring structures are connected to the intersubunit linkages and base-pairing moieties as shown in claim 2; and methods and uses thereof. It is believed that claims 1-4, 30, and 31 read on this first named invention and thus these claims will be searched without fee to the extent that they read on the above embodiment.

Applicant is invited to elect additional formula(e) for each additional compound to be searched in a specific combination by paying an additional fee for each set of election. Each additional elected formula(e) requires the selection of a single definition for each compound variable. An exemplary election would be a method for treatment of a lymphocyte-related disease or condition, the method comprising administering an effective amount of an oligomer to a patient in need thereof, wherein the oligomer comprises a backbone having a sequence of morpholino ring structures joined by intersubunit linkages, the intersubunit linkages joining a 3'-end of one morpholino ring structure to a 5'-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing moiety, such that the oligomer can bind in a sequence-specific manner to a target nucleic acid, wherein at least one of the intersubunit linkages has the structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1 is alkylaminy, L1 is C1 oxyalkylene, X is, at each occurrence, independently -O-, Y is, at each occurrence, independently -O-, and Z is an unsubstituted 6-membered heterocyclic ring, which is piperidiny, and wherein the morpholino ring structures are connected to the intersubunit linkages and base-pairing moieties as shown in claim 2; and methods and uses thereof. Additional formula(e) will be searched upon the payment of additional fees. Applicants must specify the claims that read on any additional elected inventions. Applicants must further indicate, if applicable, the claims which read on the first named invention if different than what was indicated above for this group. Failure to clearly identify how any paid additional invention fees are to be applied to the "+" group(s) will result in only the first claimed invention to be searched/examined.

The inventions listed in Groups I+ do not relate to a single general inventive concept under PCT Rule 13.1, because under PCT Rule 13.2 they lack the same or corresponding special technical features for the following reasons:

The Groups I+ formulae do not share a significant structural element requiring the selection of alternatives for compound variables R1, L1, X, Y, and Z.

The Groups I+ share the technical features of a method for treatment of a lymphocyte-related disease or condition, the method comprising administering an effective amount of an oligomer to a patient in need thereof, wherein the oligomer comprises a backbone having a sequence of morpholino ring structures joined by intersubunit linkages, the intersubunit linkages joining a 3'-end of one morpholino ring structure to a 5'-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing moiety, such that the oligomer can bind in a sequence-specific manner to a target nucleic acid, wherein at least one of the intersubunit linkages has a core structure of the structure (I); a method for treatment of a T-cell related disease or condition, the method comprising contacting activated T-cells with an oligomer comprising a backbone having a sequence of morpholino ring structures joined by intersubunit linkages, the intersubunit linkages joining a 3'-end of one morpholino ring structure to a 5'-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing moiety, such that the oligomer can bind in a sequence-specific manner to a target nucleic acid, wherein at least one of the intersubunit linkages has a core structure of the structure (I); and use of an oligomer comprising a backbone having a sequence of morpholino ring structures joined by intersubunit linkages, the intersubunit linkages joining a 3'-end of one morpholino ring structure to a 5'-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing moiety, such that the oligomer can bind in a sequence-specific manner to a target nucleic acid, wherein at least one of the intersubunit linkages has a core structure of the structure (I). However, these shared technical features do not represent a contribution over the prior art.

Specifically, "In vivo Bioavailability and Pharmacokinetics of a c-MYC Antisense Phosphorodiamidate Morpholino Oligomer, AVI-4126, in Solid Tumors" to Devi et al. teach a method for treatment of a lymphocyte-related disease or condition (Abstract, Phosphorodiamidate morpholino oligomers (PMO) inhibit targeted gene expression by preventing ribosomal assembly, thereby preventing mRNA translation. AVI-4126, a PMO targeted against c-MYC, has been extensively characterized in multiple cancer and other disease models and is currently in human clinical trials... These studies show PMO bioavailability in tumor tissue and establish the feasibility of using PMO targeting specific genes in human cancer clinical trials; Pg. 3936, Col. 2, Para. 2, c-MYC gene, the cellular homologue of the avian

myelocytic leukemia virus, is implicated in a large number of human solid tumors, leukemias, and lymphomas as well as in a variety of animal neoplasias...; Pg. 3937, Col. 2, Para. 2, In summary, this is the first study that has characterized PMO bioavailability in solid tumors and reveals the potential of PMOs as a clinically viable strategy in cancer therapeutics), the method comprising administering an effective amount of an oligomer to a patient in need thereof, wherein the oligomer comprises a backbone having a sequence of morpholino ring structures joined by intersubunit linkages, the intersubunit linkages joining a 3'-end of one morpholino ring structure to a 5'-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing moiety, such that the oligomer can bind in a sequence-specific manner to a target nucleic acid, wherein at least one of the intersubunit linkages has a core structure of the structure (I) (Abstract, Phosphorodiamidate morpholino oligomers (PMO),... AVI-4126); a method for treatment of a T-cell related disease or condition (Abstract, Phosphorodiamidate morpholino oligomers (PMO) inhibit targeted gene expression by preventing ribosomal assembly, thereby preventing mRNA translation. AVI-4126, a PMO targeted against c-MYC, has been extensively characterized in multiple cancer and other disease models and is currently in human clinical trials... These studies show PMO bioavailability in tumor tissue and establish the feasibility of using PMO targeting specific genes in human cancer clinical trials; Pg. 3936, Col. 2, Para. 2, c-MYC gene, the cellular homologue of the avian myelocytic leukemia virus, is implicated in a large number of human solid tumors, leukemias, and lymphomas as well as in a variety of animal neoplasias...; Pg. 3937, Col. 2, Para. 2, In summary, this is the first study that has characterized PMO bioavailability in solid tumors and reveals the potential of PMOs as a clinically viable strategy in cancer therapeutics), the method comprising contacting activated T-cells with an oligomer comprising a backbone having a sequence of morpholino ring structures joined by intersubunit linkages, the intersubunit linkages joining a 3'-end of one morpholino ring structure to a 5'-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing moiety, such that the oligomer can bind in a sequence-specific manner to a target nucleic acid, wherein at least one of the intersubunit linkages has a core structure of the structure (I) (Abstract, Phosphorodiamidate morpholino oligomers (PMO),... AVI-4126); and use of an oligomer comprising a backbone having a sequence of morpholino ring structures joined by intersubunit linkages (Abstract, Phosphorodiamidate morpholino oligomers (PMO) inhibit targeted gene expression by preventing ribosomal assembly, thereby preventing mRNA translation. AVI-4126, a PMO targeted against c-MYC, has been extensively characterized in multiple cancer and other disease models and is currently in human clinical trials... These studies show PMO bioavailability in tumor tissue and establish the feasibility of using PMO targeting specific genes in human cancer clinical trials; Pg. 3936, Col. 2, Para. 2, c-MYC gene, the cellular homologue of the avian myelocytic leukemia virus, is implicated in a large number of human solid tumors, leukemias, and lymphomas as well as in a variety of animal neoplasias...; Pg. 3937, Col. 2, Para. 2, In summary, this is the first study that has characterized PMO bioavailability in solid tumors and reveals the potential of PMOs as a clinically viable strategy in cancer therapeutics), the intersubunit linkages joining a 3'-end of one morpholino ring structure to a 5'-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing moiety, such that the oligomer can bind in a sequence-specific manner to a target nucleic acid, wherein at least one of the intersubunit linkages has a core structure of the structure (I) (Abstract, Phosphorodiamidate morpholino oligomers (PMO),... AVI-4126).

Additionally, US 8,697,858 B2 to Iversen teaches a method for treatment of a disease or condition (Abstract, he present invention relates to antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection...Exemplary antisense antiviral compounds are substantially uncharged, or partially positively charged, morpholino oligonucleotides having 1) a nuclease resistant backbone, 2) 12-40 nucleotide bases, and 3) a targeting sequence of at least 12 bases in length that hybridizes to a target region selected from the following: a) the 5' or 3' terminal 25 bases of the negative sense viral RNA segment of Influenzavirus A, Influenzavirus B and Influenzavirus C), the method comprising administering an effective amount of an oligomer to a patient in need thereof, wherein the oligomer comprises a backbone having a sequence of morpholino ring structures joined by intersubunit linkages, the intersubunit linkages joining a 3'-end of one morpholino ring structure to a 5'-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing moiety, such that the oligomer can bind in a sequence-specific manner to a target nucleic acid, wherein at least one of the intersubunit linkages has a core structure of the structure (I) (Col. 36, Structure b1; Col. 35, Lns. 56-65, In one embodiment, at least one linkage is of type (b1), where, preferably, each R is H, R4 is H, CH3, or an electron pair, and R3 is selected from H, lower alkyl, e.g., CH3, C(=NH)NH2, and C(O)-L-NHC(=NH)NH2. The latter two embodiments of R3 provide a guanidino moiety, either attached directly to the piperazine ring, or pendant to a linker group L, respectively); and use of an oligomer comprising a backbone having a sequence of morpholino ring structures joined by intersubunit linkages (Abstract, he present invention relates to antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection...Exemplary antisense antiviral compounds are substantially uncharged, or partially positively charged, morpholino oligonucleotides having 1) a nuclease resistant backbone, 2) 12-40 nucleotide bases, and 3) a targeting sequence of at least 12 bases in length that hybridizes to a target region selected from the following: a) the 5' or 3' terminal 25 bases of the negative sense viral RNA segment of Influenzavirus A, Influenzavirus B and Influenzavirus C), the intersubunit linkages joining a 3'-end of one morpholino ring structure to a 5'-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing moiety, such that the oligomer can bind in a sequence-specific manner to a target nucleic acid, wherein at least one of the intersubunit linkages has a core structure of the structure (I) (Col. 36, Structure b1; Col. 35, Lns. 56-65, In one embodiment, at least one linkage is of type (b1), where, preferably, each R is H, R4 is H, CH3, or an electron pair, and R3 is selected from H, lower alkyl, e.g., CH3, C(=NH)NH2, and C(O)-L-NHC(=NH)NH2. The latter two embodiments of R3 provide a guanidino moiety, either attached directly to the piperazine ring, or pendant to a linker group L, respectively).

The inventions listed in Groups I+ therefore lack unity under Rule 13 because they do not share a same or corresponding special technical feature.